Heterobifunctional monodisperse polyethylene glycols with peptide linkers
A heterobifunctional monodisperse polyethylene glycol with closely bonded side chains addresses hydrophobicity issues in ADCs, enhancing drug release and stability, thus improving ADC efficacy.
Patent Information
- Application Number
- JP2021549023
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-26
- Filing Date
- 2020-09-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-09-25
AI Technical Summary
Existing antibody-drug conjugates (ADCs) face issues with hydrophobic drug aggregation and decreased antibody stability due to hydrophobicity, limiting drug loading and efficacy, and current branched polyethylene glycol linkers do not effectively shield drugs or maintain antibody stability in blood.
A heterobifunctional monodisperse polyethylene glycol with two closely bonded monodisperse polyethylene glycol side chains, connected via a peptide linker, which is decomposed by intracellular enzymes to sustainably release drugs while shielding hydrophobicity.
The solution provides a highly homogeneous ADC with improved drug release and stability, reducing aggregation and maintaining antibody functionality.
Smart Images

Figure 0007593323000058 
Figure 0007593323000059 
Figure 0007593323000060
Abstract
Description
[Technical field]
[0001] The present invention relates to a peptide linker and a heterobifunctional monodisperse polyethylene glycol having two different chemically reactive functional groups. More specifically, the present invention relates to a peptide linker and a heterobifunctional monodisperse polyethylene glycol having two different chemically reactive functional groups, which is used for modifying biofunctional molecules such as physiologically active proteins, peptides, antibodies, nucleic acids, and low-molecular-weight drugs, drug carriers in drug delivery systems, or diagnostic materials and medical devices, and is particularly useful for modifying antibody drugs. [Background technology]
[0002] Antibody-drug conjugates (ADCs) are antibody drugs that are designed to deliver drugs to disease sites by conjugating the drugs to antibodies and utilizing the antigen specificity of the antibodies. In recent years, ADCs are one of the fastest growing technologies in the field of cancer treatment. ADCs consist of an antibody, a drug, and a linker that connects the antibody and the drug.
[0003] Many of the drugs used in ADCs are hydrophobic, and when multiple hydrophobic drugs are bound to an antibody to prepare an ADC, problems arise such as aggregation due to the hydrophobicity of the drugs and reduced stability of the antibody in the blood. This places a limit on the number of drugs that can be loaded onto one antibody, and as a result, the efficacy of the ADC may not be fully achieved.
[0004] One of the solutions being considered to this issue is the use of hydrophilic linkers, such as polyethylene glycol, hydrophilic peptides, and sugar chains. Polyethylene glycol in particular has low antigenicity and high biocompatibility, and is therefore used in several ADCs currently in clinical trials and preclinical trials.
[0005] In the ADC field, compounds containing at least 90% of a specific ethylene glycol chain length are used to ensure the homogeneity of ADCs and to facilitate purification, analysis, and drug approval applications. Such compounds are called monodisperse polyethylene glycols.
[0006] When monodisperse polyethylene glycol is used as a linker for ADC, it is necessary to bind the antibody and the drug separately, so heterobifunctional monodisperse polyethylene glycol having two different chemically reactive functional groups is used. In general, ADCs are prepared using a compound having different chemically reactive functional groups at both ends of a monodisperse polyethylene glycol chain.
[0007] However, in recent years, ADCs have been reported in which monodisperse polyethylene glycol is introduced as a side chain in a branched linker connecting the antibody and drug, rather than using monodisperse polyethylene glycol as the main chain of the linker connecting the antibody and drug.
[0008] Non-Patent Document 1 compares the pharmacokinetics and therapeutic effects of an ADC that uses monodisperse polyethylene glycol as the main chain of a linker that connects an antibody and a drug, and an ADC that uses monodisperse polyethylene glycol as a side chain of a branched linker that connects an antibody and a drug, and reports that the latter has a higher effect of masking the hydrophobicity of the drug and shows superior pharmacokinetics and therapeutic effects.
[0009] Furthermore, Patent Documents 1 and 2 disclose various types of ADCs having monodisperse polyethylene glycol as a side chain of a branched linker, and intermediates for preparing these.
[0010] Furthermore, Patent Document 3 discloses a heterobifunctional monodisperse polyethylene glycol having a four-branched skeleton in which two monodisperse polyethylene glycols are bonded to a quaternary carbon atom and which has two types of functional groups at two ends of the branches, and an ADC using the same. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] International Publication No. 2015 / 057699 Brochure [Patent Document 2] International Publication No. 2016 / 063006 Brochure [Patent Document 3] International Publication No. 2018 / 181059 Brochure [Non-patent literature]
[0012] [Non-Patent Document 1] Nature Biotechnology, 2015, 33, 733-735 DISCLOSURE OF THEINVENTION [Problem to be solved by the invention]
[0013] Patent Documents 1 and 2 also disclose ADCs having two or more monodisperse polyethylene glycols in the side chains of a branched linker. However, the binding positions of each monodisperse polyethylene glycol side chain are far apart, and the shielding effect of hydrophobic drugs due to the "umbrella-like" structure (Biomaterials 2001, 22(5), 405-417), which is a characteristic of branched polyethylene glycol having multiple polyethylene glycol chains, is small, and the advantage of having multiple monodisperse polyethylene glycol side chains cannot be effectively utilized.
[0014] Furthermore, Non-Patent Document 1 and Patent Document 3 disclose branched monodisperse polyethylene glycol having monodisperse polyethylene glycol in the side chain of a branched linker, and an ADC using the same for binding an antibody to a drug. However, after this ADC is taken up into a cell, the antibody is degraded by an enzyme in the cell, but the monodisperse polyethylene glycol remains bound to the drug, which may reduce the activity of the drug, and is therefore undesirable.
[0015] The present invention relates to an antibody-drug conjugate in which an antibody and a drug are linked by a linker having a peptide linker and a monodisperse polyethylene glycol side chain. That is, the object of the present invention is to provide a heterobifunctional monodisperse polyethylene glycol having two adjacent monodisperse polyethylene glycol side chains that can be decomposed by an intracellular enzyme to slowly release the drug and can effectively mask the hydrophobicity of the drug, and an antibody-drug conjugate in which an antibody and a drug are bound using the same. [Means for solving the problem]
[0016] Means for Solving the Problems The present inventors have conducted intensive research to solve the above problems, and as a result have developed a heterobifunctional monodisperse polyethylene glycol, which is a heterobifunctional compound having a peptide linker that is degraded by an intracellular enzyme and in which two monodisperse polyethylene glycol side chains are closely bound, and an antibody-drug conjugate in which an antibody and a drug are conjugated using the same.
[0017] Furthermore, the heterobifunctional monodisperse polyethylene glycol of the present invention has two monodisperse polyethylene glycol side chains bonded to the quaternary carbon atom of the branched portion via a stable ether bond, and therefore has the characteristic that the heterobifunctional monodisperse polyethylene glycol is unlikely to be decomposed into a single-chain monodisperse polyethylene glycol in a chemical conversion process of the structure.
[0018] In addition, the heterobifunctional monodisperse polyethylene glycol of the present invention has a peptide linker that is degraded by intracellular enzymes, and therefore has the characteristic of being able to effectively sustained-release a drug within a cell without affecting the activity of the drug within the cell.
[0019] That is, the present invention is as follows. [1] A heterobifunctional monodisperse polyethylene glycol represented by formula (1):
[0020] [ka]
[0021] (In formula (1), X 1 and Y 1 are atomic groups each containing at least a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, and the atomic group X 1 The functional group and the atomic group Y 1 are different from each other; R 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer from 3 to 72; A 1 -L 1 -(CH2) m1 -L 2 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 represents -, an amide bond, a urethane bond, a secondary amino group, or a single bond, and m1 and m2 each independently represent an integer of 1 to 5; B 1 Ha-CH2-L 3 -, -CH2-L 3 -(CH2) m3 -L 4 -or-CH2-L 3 -(CH2) m3 -L 4 -(CH2) m4 -, m3 and m4 each independently represent an integer of 1 to 5; W is an oligopeptide of 2 to 4 residues; Z is a spacer having a bifunctional para-aminobenzyl alcohol group attached to the C-terminus of the peptide; a1 and a2 are such that when a1=1, a2=0, and when a1=0, a2=1; b is 0 or 1; C 1 -L 5 -(CH2) m5 -, -L 5 -(CH2) m5 -L 6 -(CH2) m6-, an amide bond or a single bond, and m5 and m6 each independently represent an integer of 1 to 5; L 1 ~L 6 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, a carbonyl group, or a single bond.
[0022] [2] The heterobifunctional monodisperse polyethylene glycol according to [1], wherein W is an oligopeptide of 2 to 4 residues containing at least one hydrophobic neutral amino acid selected from the group consisting of phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
[0023] [3] The heterobifunctional monodisperse polyethylene glycol according to [1], wherein W is an oligopeptide of 2 to 4 residues containing at least one hydrophobic neutral amino acid selected from the group consisting of phenylalanine, leucine, valine, and isoleucine, and the other amino acids having at least one of alanine, glycine, citrulline, proline, serine, and asparagine.
[0024] [4] The heterobifunctional monodisperse polyethylene glycol according to [1], wherein W is an oligopeptide in which the C-terminal amino acid is glycine.
[0025] [5] The heterobifunctional monodisperse polyethylene glycol according to [1], wherein W is a dipeptide.
[0026] [6] X in Equation (1) 1 and Y 1 are each independently selected from the group consisting of formula (a), formula (b1), formula (b2), formula (c), formula (d1), formula (d2), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), formula (k), formula (l), formula (m), formula (n), and formula (o). The heterobifunctional monodisperse polyethylene glycol according to any one of [1] to [5].
[0027] [ka]
[0028] (In formulas (d1) and (d2), R 2 is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms; in formula (e), R 3 is a halogen atom selected from a chlorine atom, a bromine atom, and an iodine atom; and in formula (l), R 4 is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms.
[0029] [7] An antibody-drug conjugate comprising a heterobifunctional monodisperse polyethylene glycol represented by formula (2):
[0030] [ka]
[0031] (In formula (2), X 2 and Y 2 and one is an antibody and the other is a drug; R 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer from 3 to 72; A 2 -L 1 -(CH2) m1 -L 7 -, -L 1 -(CH2) m1 -L 8 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 -L 8 -or-L 8 -, and m1 and m2 each independently represent an integer of 1 to 5; B 2 Ha-CH2-L 9 -, -CH2-L 9 -(CH2) m3 -L 10 -, -CH2-L 9 -(CH2) m3 -L 10 -(CH2)m4 -L 11 -, -CH2-L 12 -, -CH2-L 9 -(CH2) m3 -L 12 -or-CH2-L 9 -(CH2) m3 -L 10 -(CH2) m4 -L 12 -, m3 and m4 each independently represent an integer of 1 to 5; L 1 and L 2 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, or a single bond; L 7 , L 9 , L 10 and L 11 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, or a carbonyl group; L 8 and L 12 represents an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing any of these, or a single bond; W is an oligopeptide of 2 to 4 residues; Z is a spacer having a bifunctional para-aminobenzyl alcohol group attached to the C-terminus of the peptide; a3 and a4 are X 2 When is a drug, a3=1 and a4=0, and Y 2 When is a drug, a3=0 and a4=1; b is 0 or 1; and C 2 represents an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing any of these.
[0032] [8] The antibody-drug conjugate according to [7], wherein W is an oligopeptide of 2 to 4 residues containing at least one hydrophobic neutral amino acid selected from the group consisting of phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
[0033] [9] The antibody-drug conjugate according to [7], wherein W is an oligopeptide of 2 to 4 residues containing at least one of hydrophobic neutral amino acids, phenylalanine, leucine, valine, and isoleucine, and the other amino acids having at least one of alanine, glycine, citrulline, proline, serine, and asparagine.
[0034]
[10] The antibody-drug conjugate according to [7], wherein W is an oligopeptide whose C-terminal amino acid is glycine.
[0035]
[11] The antibody-drug conjugate described in [7], wherein W is a dipeptide. Effect of the Invention
[0036] The heterobifunctional monodisperse polyethylene glycol according to the present invention is difficult to decompose into a single-chain monodisperse polyethylene glycol in a chemical conversion process because two monodisperse polyethylene glycol side chains are bonded to the quaternary carbon atom of the branched portion via a stable ether bond. Therefore, by binding an antibody and a drug using the heterobifunctional monodisperse polyethylene glycol, a highly homogeneous antibody-drug conjugate can be obtained.
[0037] Furthermore, since the heterobifunctional monodisperse polyethylene glycol has two monodisperse polyethylene glycol side chains bonded in close proximity to each other, it has a large shielding effect for hydrophobic drugs when preparing an antibody-drug conjugate, and can suppress the occurrence of aggregation due to the hydrophobicity of the drug and the decrease in the stability of the antibody in the blood.
[0038] Furthermore, since the heterobifunctional monodisperse polyethylene glycol contains a peptide linker that is degraded by an enzyme in a cell, the linker site is cleaved from the drug in the cell, and the drug can be effectively sustained-released in the cell. [Brief description of the drawings]
[0039]
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
[0040] The present invention will be described in detail below. As used herein, "heterobifunctional" means having two different chemically reactive functional groups, "monodisperse polyethylene glycol" means a compound containing at least 90% components having a specific ethylene glycol chain length, and "linker" means a chemical moiety that covalently attaches an antibody to a drug or contains a carbon chain.
[0041] The heterobifunctional monodisperse polyethylene glycol of the present invention is represented by formula (1).
[0042] [ka]
[0043] R in formula (1) of the present invention 1 R is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom, and specific examples of the hydrocarbon group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group, a phenyl group, and a benzyl group. 1 A preferred embodiment of is a methyl group or a hydrogen atom, and more preferably a methyl group.
[0044] In formula (1) of the present invention, n is an integer of 3 to 72, preferably an integer of 4 to 48, more preferably an integer of 6 to 36, and particularly preferably an integer of 8 to 24, representing the number of repeating units of the monodisperse polyethylene glycol.
[0045] In this specification, the atomic group X in formula (1) 1 and Y 1are different from each other, and are not particularly limited as long as they are atomic groups that contain at least a functional group that reacts with a functional group present in a biofunctional molecule (such as a physiologically active protein, peptide, antibody, nucleic acid, or small molecule drug) to be modified by the heterobifunctional monodisperse polyethylene glycol to form a covalent bond. Examples of the functional group include those described in "Hermanson, GT Bioconjugate Techniques, 2nd ed.; Academic Press: San Diego, CA, 2008", "Harris, JM Poly(Ethylene Glycol) Chemistry; Plenum Press: New York, 1992" and "PEGylated Protein Drugs: Basic Science and Clinical Applications; Veronese, FM, Ed.; Birkhauser: Basel, Switzerland, 2009".
[0046] Among them, X 1 and Y 1Each of the functional groups contained in each of the above is preferably a functional group that can react with a functional group (such as an amino group, a thiol group, an aldehyde group, or a carboxyl group) present in a natural biofunctional molecule, such as a protein, or a functional group (such as a maleimide group, a ketone group, an azide group, or an alkynyl group) that can be artificially introduced into the biofunctional molecule, under mild reaction conditions and with high reaction efficiency. More specifically, an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinyl sulfone group, an acryl group, a sulfonyloxy group, a carboxy group, a thiol group, a 2-pyridyldithio group, an α-haloacetyl group, a hydroxy group, an alkynyl group, an allyl group, a vinyl group, an amino group, an oxyamino group, a hydrazide group, an azide group, and a dibenzocyclooctyne (DBCO) group are preferred, and further, taking into consideration the reaction efficiency, an active ester group, an active carbonate group, a maleimide group, an α-haloacetyl group, an alkynyl group, an azide group, and a dibenzocyclooctyne (DBCO) group are preferred, and an active ester group, an active carbonate group, and a maleimide group are more preferred.
[0047] More specifically, X 1 and Y 1The functional groups contained in each of the following are independently selected from the group consisting of an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinyl sulfone group, an acryl group, a sulfonyloxy group, and a carboxy group when the functional group present in the biofunctional molecule to be modified is an amino group, and an active ester group, an active carbonate group, an aldehyde group, an isocyanate group, an isothiocyanate group, an epoxy group, a maleimide group, a vinyl sulfone group, an acryl group, a sulfonyloxy group, a carboxy group, a thiol group, a 2-pyridyldithio group, an α-haloacetyl group, an alkynyl group, It is an allyl group or a vinyl group; when the functional group present in the biofunctional molecule to be modified is an aldehyde group or a carboxy group, it is a thiol group, a hydroxyl group, an amino group, an oxyamino group or a hydrazide group; when the functional group present in the biofunctional molecule to be modified is an alkynyl group, it is a thiol group or an azide group; when the functional group present in the biofunctional molecule to be modified is an azide group, it is an alkynyl group and a dibenzocyclooctyne group; and when the functional group present in the biofunctional molecule to be modified is a halogenated alkyl group, an alkylsulfonate ester or an arylsulfonate ester, it is a thiol group, a hydroxyl group or an amino group.
[0048] Here, the term "active ester group" refers to an activated carboxy group represented by the formula: -C(=O)-E, where E represents a leaving group. Examples of the leaving group represented by E include succinimidyloxy group, phthalimidyloxy group, 4-nitrophenoxy group, 1-imidazolyl group, pentafluorophenoxy group, benzotriazol-1-yloxy group, and 7-azabenzotriazol-1-yloxy group, with succinimidyloxy group and 4-nitrophenoxy group being preferred. The term "active carbonate group" refers to an activated carbonate group represented by the formula: -OC(=O)-E, where E represents the same leaving group as above.
[0049] In a preferred embodiment of the present invention, X 1and Y 1 each independently represents a group represented by group (I), group (II), group (III), group (IV), group (V) or group (VI). Group (I): Functional groups capable of reacting with amino groups of biofunctional molecules to form covalent bonds (a), (b1), (b2), (c), (d1), (d2), (e) and (f) below. Group (II): Functional groups capable of reacting with a thiol group of a biofunctional molecule to form a covalent bond (a), (b1), (b2), (c), (d1), (d2), (e), (f), (g), (h) and (l) below. Group (III): Functional groups capable of reacting with an aldehyde group or a carboxyl group of a biofunctional molecule to form a covalent bond. (g), (i), (j), (k) and (o) below. Group (IV): Functional groups capable of reacting with an alkynyl group of a biofunctional molecule to form a covalent bond Items (g), (i), (j), (k) and (n) below. Group (V): Functional groups capable of reacting with an azide group of a biofunctional molecule to form a covalent bond (l) and (m) below Group (VI): Functional groups capable of reacting with a halogenated alkyl group, an alkylsulfonate ester, or an arylsulfonate ester of a biofunctional molecule to form a covalent bond. Items (g), (i) and (o) below.
[0050] [ka]
[0051] In the formula, R 2 , R 4 R is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms, and specific examples of the hydrocarbon group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a t-butyl group, and a pentyl group. 3 is a halogen atom selected from a chlorine atom, a bromine atom, and an iodine atom.
[0052] The atomic group X in formula (1) 1 and Y 1 Preferred combinations of functional groups included in X 1 When the functional group contained in is an active ester group or an active carbonate group, Y 1 The functional group contained in X is a group selected from a maleimide group, a vinyl sulfone group, an α-haloacetyl group, an alkynyl group, and an azide group; 1 When the functional group in is an aldehyde group, Y 1 The functional group contained in X is a group selected from a maleimide group, a vinyl sulfone group, an alkynyl group, and an azide group; 1 When the functional group contained in is a maleimide group, a vinyl sulfone group, or an α-haloacetyl group, Y 1 The functional group contained in X is a group selected from an active ester group, an active carbonate group, an alkynyl group, and an azide group; 1 When the functional group contained in is an alkynyl group or an azide group, Y 1 The functional group contained in X is a group selected from a maleimide group, a vinyl sulfone group, an α-haloacetyl group, an active ester group, an active carbonate group, an amino group, an oxyamino group, and a hydroxy group; 1 When the functional group in is an amino group or an oxyamino group, Y 1 The functional group contained in X is an alkynyl group, an azide group, a thiol group, a hydroxyl group, or a carboxyl group; 1 When the functional group contained in is a thiol group, a 2-pyridyldithio group, or a hydroxyl group, Y 1 is a group selected from an amino group, an oxyamino group, an azide group, and a carboxy group. More preferably, X 1 When the functional group contained in is an active ester group or an active carbonate group, Y 1 The functional group contained in X is a group selected from a maleimide group, an α-haloacetyl group, an alkynyl group, and an azide group; 1 When the functional group in is an aldehyde group, Y 1The functional group contained in X is a group selected from a maleimide group, an α-haloacetyl group, an alkynyl group, and an azide group; 1 When the functional group contained in is a maleimide group or an α-haloacetyl group, Y 1 The functional group contained in X is a group selected from an active ester group, an active carbonate group, an alkynyl group, and an azide group; 1 When the functional group contained in is an alkynyl group or an azide group, Y 1 The functional group contained in X is a group selected from a maleimide group, an α-haloacetyl group, an active ester group, an active carbonate group, an amino group, an oxyamino group, and a hydroxy group; 1 When the functional group in is an amino group or an oxyamino group, Y 1 The functional group contained in X is an alkynyl group, an azide group, a hydroxyl group, or a thiol group. 1 When the functional group contained in is a thiol group, a 2-pyridyldithio group, or a hydroxyl group, Y 1 The functional group contained in is a group selected from an amino group, an oxyamino group, and an azide group.
[0053] W in formula (1) is a degradable linker that is specifically cleaved by intracellular lysosomal enzymes. Such linkers are, for example, peptide-based structures. Degradable peptide linkers generally have good blood stability because lysosomal enzymes are only activated in the low pH environment of intracellular lysosomes. Drug release from the antibody occurs specifically through the action of lysosomal enzymes, such as cathepsin and plasmin. These enzymes may be present at high levels in certain tumor tissues. In certain embodiments, the linker can be cleaved by lysosomal enzymes, such as cathepsin B.
[0054] W in formula (1) is not particularly limited as long as it is an oligopeptide of 2 to 4 residues that is stable in the blood of the living body and is degraded by intracellular enzymes, but it is preferable to use an oligopeptide containing more hydrophilic amino acids in order to maximally mask the hydrophobicity of the drug during preparation of the antibody-drug conjugate and to suppress aggregation due to the hydrophobicity of the drug. In certain embodiments, dipeptides are more preferable than longer peptides because longer peptides are hydrophobic.
[0055] On the other hand, cathepsin B, a lysosomal enzyme, has the property of efficiently hydrolyzing oligopeptides having highly hydrophobic amino acids (Vieira Portaro, FC et al. Biochem. J. 2000, 347:123-129; Cezari, MHS et al. Biochem.J. 2002, 368:365-369). Therefore, W in formula (1) is preferably a hydrophobic neutral amino acid having a hydropathic index of 2.5 or more, specifically, an oligopeptide of 2 to 4 residues having at least one of phenylalanine, leucine, valine, and isoleucine, and more preferably an oligopeptide of 2 to 4 residues having valine or phenylalanine. The hydropathy index, developed by Kyte and Doolittle, is a quantitative indicator of the hydrophobicity of amino acids, with a higher value indicating a more hydrophobic amino acid (Kyte J & Doolittle RF, 1982, J Mol Biol, 157:105-132.).
[0056] As the amino acid to be combined with the hydrophobic amino acid, W in formula (1) is preferably a neutral amino acid having a LogP value calculated by XLogP3 smaller than -2.5, specifically, an oligopeptide of 2 to 4 residues having at least one of alanine, glycine, citrulline, proline, serine, and asparagine, and more preferably an oligopeptide of 2 to 4 residues having at least one of alanine, glycine, and citrulline. Here, "LogP" is defined as the logarithm of the octanol / water partition coefficient, and is a value that serves as an index of hydrophobicity, and the smaller the value, the more hydrophilic the compound is. "XlogP3" is a method for calculating the LogP value created by Cheng et al. (Cheng, T. et al. J Chem Inf Model. 2007, 47:2140-2148).
[0057] In addition, W in formula (1) is preferably an oligopeptide of 2 to 4 residues having glycine as the C-terminal amino acid. When reacting the C-terminal carboxyl group, it is basically necessary to activate the C-terminal carboxyl group with a condensing agent or the like. In this activation process, epimerization is likely to occur with amino acids other than glycine, and it is known that stereoisomers are replicated. By making the C-terminal amino acid of the oligopeptide achiral glycine, it is possible to obtain a highly pure target product without the by-product of stereoisomers.
[0058] In addition, W in formula (1) is preferably an oligopeptide of 2 to 4 residues composed of an amino acid having an amino group or a carboxyl group in the side chain, specifically, an amino acid not containing lysine, aspartic acid, or glutamic acid. In the synthesis of the heterobifunctional monodisperse polyethylene glycol in formula (1) of the present invention, when an oligopeptide is introduced into the polyethylene glycol portion, the amino group at the N-terminus or the carboxyl group at the C-terminus of the oligopeptide is used in the reaction. However, when an amino acid having an amino group or a carboxyl group in the side chain is contained in the oligopeptide, impurities are generated in which the polyethylene glycol portion is introduced not only into the amino group at the N-terminus or the carboxyl group at the C-terminus of interest, but also into the amino group or the carboxyl group at the side chain. Since it is difficult to remove these impurities by purification processes such as normal extraction and crystallization, it is desirable to use an oligopeptide composed of an amino acid not containing an amino group or a carboxyl group in the side chain in order to obtain the target product with high purity. The amino acid used here is an α-amino acid, and is basically L-type.
[0059] Furthermore, since cysteine, a neutral amino acid, has a thiol group and forms a disulfide bond with another thiol group, W in formula (1) is preferably an oligopeptide composed of amino acids that do not contain cysteine.
[0060] W in formula (1) is not particularly limited as long as it is stable in blood in a living body and has the ability to be decomposed by an intracellular enzyme, and is an oligopeptide of 2 to 4 residues consisting of neutral amino acids excluding cysteine. Specific examples include glycine-phenylalanine-leucine-glycine, glycine-glycine-phenylalanine-glycine, glycine-phenylalanine-glycine, glycine-leucine-glycine, valine-citrulline-glycine, valine-alanine-glycine, valine-citrulline, valine-alanine, phenylalanine-glycine, etc., preferably glycine-phenylalanine-leucine-glycine, glycine-glycine-phenylalanine-glycine, valine-citrulline-glycine, valine-alanine-glycine, valine-citrulline, valine-alanine, phenylalanine-glycine, more preferably valine-citrulline, valine-alanine, or phenylalanine-glycine, and even more preferably valine-citrulline.
[0061] Z in formula (1) is a self-degrading spacer that further separates the drug from the site where the peptide linker represented by W is cleaved by the enzyme. If the drug and the peptide linker are directly bonded, the peptide linker portion may remain on the drug when the peptide linker is cleaved, which may result in a decrease in the activity of the drug. By using a self-degrading spacer, it is possible to release the drug without the peptide linker when the amide bond is hydrolyzed.
[0062] One of the autolytic spacers is a bifunctional para-aminobenzyl alcohol group, which is linked to the peptide via the amino group to form an amide bond, while a drug having an amino or hydroxyl group can be linked to the benzyl alcohol group of the linker via a carbamate or carbonate bond (to give para-aminobenzyl carbamate or para-aminobenzyl carbonate). The resulting prodrug is activated upon cleavage of the amide bond between the peptide and the linker, resulting in a 1,6-elimination reaction, releasing the drug without the peptide linker, carbon dioxide, and the remaining part of the linker group. This group is not necessarily required when the C-terminus of the peptide linker is on the monodisperse polyethylene glycol side and not on the drug side, since it only causes an elimination reaction when the amide bond on the C-terminus of the peptide linker is cleaved, releasing the drug without the peptide linker. The following scheme illustrates the fragmentation of para-amidobenzyl carbamate or para-amidobenzyl carbonate, and the release of the drug:
[0063] [ka]
[0064] (wherein X represents a drug without a peptide linker.)
[0065] In formula (1), b is 0 or 1. When b is 0, the autodecomposable spacer represented by Z in formula (1) is not included, and when b is 1, the autodecomposable spacer represented by Z in formula (1) is included.
[0066] A in formula (1) of the present invention 1 is a quaternary carbon atom in the branch and W or X 1 In formula (1), B is a divalent spacer between 1 is a quaternary carbon atom in the branched part and W or Y 1 and C in formula (1) is a divalent spacer between 1 Z and X 1 or Y 1are divalent spacers between the
[0067] Specifically, A 1 -L 1 -(CH2) m1 -L 2 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 represents -, an amide bond, a urethane bond, a secondary amino group, or a single bond, and is preferably -L 1 -(CH2) m1 -L 2 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 -, amide bond, secondary amino group, and more preferably -L 1 -(CH2) m1 -L 2 -(CH2) m2 In the formula, m1 and m2 each independently represent an integer of 1 to 5.
[0068] Also, B 1 Ha-CH2-L 3 -, -CH2-L 3 -(CH2) m3 -L 4 -or-CH2-L 3 -(CH2) m3 -L 4 -(CH2) m4 -, preferably -CH2-L 3 -or-CH2-L 3 -(CH2) m3 -L 4 In the formula, m3 and m4 each independently represent an integer of 1 to 5.
[0069] Furthermore, C 1 -L 5 -(CH2) m5 -, -L 5 -(CH2) m5 -L 6 -(CH2) m6In the formula, m5 and m6 each independently represent an integer of 1 to 5.
[0070] In the above formula, L 1 ~L 6 are each independently a divalent spacer, specifically, an ether bond, a urethane bond, an amide bond, a secondary amino group, a carbonyl group, or a single bond.
[0071] In addition, L 1 and L 2 are each independently preferably a urethane bond, an amide bond or a secondary amino group; L 3 is preferably an ether bond, a urethane bond or a single bond, and L 4 is preferably an amide bond, a urethane bond, a secondary amino group, a carbonyl group or a single bond, and L 5 is preferably a urethane bond, and L 6 is preferably an amide bond, a urethane bond or a secondary amino group.
[0072] In the present invention, a1 and a2 in formula (1) are each -W-(Z) b -C 1 - indicates the presence or absence of a spacer moiety, and in certain embodiments, when a1=1, a2=0, and in certain other embodiments, when a1=0, a2=1.
[0073] A typical synthesis example of the heterobifunctional monodisperse polyethylene glycol of formula (1) in a preferred embodiment of the present invention will be described below, but the present invention is not limited thereto.
[0074] (A) The heterobifunctional monodisperse polyethylene glycol of formula (1) in a preferred embodiment of the present invention can be produced, for example, by the following steps.
[0075] [ka]
[0076] (In formula (3), P 1 is a protecting group for the amino group; and P 2 is a protecting group for a hydroxy group.
[0077] The compound represented by the formula (3) is subjected to a nucleophilic substitution reaction with an alkyl or aryl sulfonate ester of monomethyl monodispersed polyethylene glycol or a halide of monomethyl monodispersed polyethylene glycol in an anhydrous solvent in the presence of a strong base to obtain a compound represented by the following formula (4).
[0078] Here, a "protecting group" is a component that prevents or inhibits the reaction of a specific functional group in a molecule under certain reaction conditions. Protecting groups vary depending on the type of functional group to be protected, the conditions used, and the presence of other functional groups or protecting groups in the molecule. Specific examples of protecting groups can be found in many general textbooks, for example, "Wuts, PGM; Greene, TW Protective Groups in Organic Synthesis, 4th ed.; Wiley-Interscience: New York, 2007". In addition, functional groups protected with protecting groups can be deprotected, i.e., chemically reacted, using reaction conditions appropriate for each protecting group to regenerate the original functional group. Representative deprotection conditions for protecting groups are described in the above-mentioned literature.
[0079] As a preferred combination of a functional group to be protected and a protecting group, when the functional group to be protected is an amino group, for example, an acyl protecting group and a carbamate protecting group are mentioned, specifically, a trifluoroacetyl group, a 9-fluorenylmethyloxycarbonyl group, a t-butyloxycarbonyl group, a 2-(trimethylsilyl)ethyloxycarbonyl group, etc., and when the functional group to be protected is a hydroxy group, for example, a silyl protecting group and an acyl protecting group are mentioned, specifically, a t-butyldiphenylsilyl group, a t-butyldimethylsilyl group, a triisopropylsilyl group, an acetyl group, a pivaloyl group, etc.
[0080] When the functional group to be protected is a carboxyl group, examples of the protecting groups include alkyl ester-based and silyl ester-based protecting groups, specifically, methyl, 9-fluorenylmethyl, and t-butyldimethylsilyl groups. When the functional group to be protected is a sulfanyl group, examples of the protecting groups include thioether-based, thiocarbonate-based, and disulfide-based protecting groups, specifically, S-2,4-dinitrophenyl, S-9-fluorenylmethyloxycarbonyl, and St-butyldisulfide groups. Bifunctional protecting groups capable of simultaneously protecting two functional groups of the same or different types may also be used. Preferred combinations of the functional group to be protected and the protecting group, when the functional group to be protected is two hydroxy groups, include, for example, cyclic acetal-based protecting groups and cyclic silyl-based protecting groups, specifically 2,2-dimethyl-1,3-dioxolane group, 2,2-dimethyl-1,3-dioxane group, 2-phenyl-1,3-dioxane group, 2-phenyl-1,3-dioxane group, di-t-butylsilylene group, etc. When the functional groups to be protected are amino and hydroxy groups, for example, oxazoline-based protecting groups, specifically 2-phenyloxazoline group, etc., are included.
[0081] Representative deprotection conditions for the protecting groups are described in the above-mentioned documents, and reaction conditions suitable for each protecting group can be selected. However, if the functional group contained in the structure is a functional group that does not inhibit the chemical reaction of other functional groups even if it is not protected by a protecting group, there is no need to use a protecting group.
[0082] [ka]
[0083] The protecting group P of the compound represented by the formula (4) 1 After deprotection, the amino group at the N-terminus is converted to a protecting group P in the presence of a condensing agent. 3The oligopeptide protected by the protecting group P is reacted to obtain a compound represented by the following formula (5). Here, if reaction conditions are selected such that the hydroxy group does not react with the reaction reagent for the amino group, the protecting group P 1 At the same time, the protecting group P 2 In addition, Peptide in the following formula (5) is an oligopeptide having the same meaning as W above.
[0084] [ka]
[0085] The protecting group P of the compound represented by the formula (5) 2 After deprotection, the compound is converted into an active carbonate using an active carbonation reagent in the presence of a base, and the active carbonate is then reacted with a carboxylic acid having an amino group to obtain a compound represented by the following formula (6). The active carbonation reagent is not particularly limited, and examples thereof include p-nitrophenyl chloroformate, di(N-succinimidyl) carbonate, etc. In addition, m3 in the following formula (6) has the same meaning as above.
[0086] [ka]
[0087] Furthermore, the protecting group P of the compound represented by the formula (6) 3 By deprotecting the compound, a compound represented by the following formula (7) is obtained.
[0088] [ka]
[0089] In another preferred embodiment of this step, the protecting group P of the compound represented by formula (5) is 2 After deprotection, the carboxylic acid is reacted with an acrylic ester in the presence of a strong base, and a protecting group P is further added. 3The protecting group of the carboxylic acid is then deprotected to obtain a compound represented by the following formula (8). Note that m3 in the following formula (8) has the same meaning as above, and the acrylic acid ester used in the reaction is not particularly limited as long as the number of carbon atoms satisfies m3, but specifically, t-butyl acrylate or the like is used.
[0090] [ka]
[0091] (B) In another preferred embodiment of the present invention, the heterobifunctional monodisperse polyethylene glycol of formula (1) can be produced, for example, by the following steps.
[0092] The protecting group P of the compound represented by the formula (4) 2 After deprotection, the amino group is converted to a protecting group P in the presence of a condensing agent. 4 A compound represented by the following formula (9) is obtained by reacting a carboxylic acid protected by the following formula (9): In addition, m1 and m3 in the following formula (9) are as defined above.
[0093] [ka]
[0094] The compound represented by the formula (9) is reacted with an oligopeptide derivative in which the amino group at the N-terminus is unprotected and the C-terminus is condensed with para-aminobenzyl alcohol in the presence of a condensing agent, and then a protecting group P 4 is deprotected to obtain a compound represented by the following formula (10): Peptide in the following formula (10) has the same meaning as defined above.
[0095] [ka]
[0096] The compounds represented by the formulas (7), (8) and (10) each have one amino group, and by utilizing this, the X1 It is possible to convert the functional group to the functional group shown in
[0097] The step of converting the terminal amino groups of the heterobifunctional monodisperse polyethylene glycol to other functional groups is not particularly limited, but basically, the amino groups can be converted to various functional groups by using a compound having an active ester group capable of reacting with an amino group, or a general reaction reagent such as an acid anhydride or an acid chloride.
[0098] For example, when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol to a maleimide group, the target product can be obtained by reacting it with a reagent such as the following.
[0099] [ka]
[0100] For example, when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol to a carboxyl group, the target product can be obtained by reacting it with succinic anhydride or glutaric anhydride.
[0101] For example, when it is desired to convert the amino group at the terminal of the heterobifunctional monodisperse polyethylene glycol to a hydroxyl group, the target product can be obtained by a condensation reaction with a ring-opening product of a cyclic ester such as caprolactone.
[0102] In addition, the compounds represented by the formulas (6), (7), (8) and (9) all have one carboxylic acid, and the compound represented by the formula (10) has one hydroxyl group. 1 It is possible to convert the functional group to the functional group shown in
[0103] The step of converting the terminal carboxylic acid of the heterobifunctional monodisperse polyethylene glycol to another functional group is not particularly limited. For example, a compound capable of converting a carboxylic acid to an active ester group, specifically, a reagent such as N-hydroxysuccinimide, can be reacted in the presence of a condensing agent to convert the carboxylic acid to various functional groups.
[0104] The step of converting the terminal hydroxyl groups of the heterobifunctional monodisperse polyethylene glycol to other functional groups is not particularly limited. For example, a hydroxyl group can be converted to various functional groups by using a compound capable of converting a hydroxyl group to an active carbonate group, specifically, an active carbonation reagent such as p-nitrophenyl chloroformate or di(N-succinimidyl) carbonate.
[0105] In another aspect of the present invention, there is provided an antibody-drug conjugate comprising a heterobifunctional monodisperse polyethylene glycol having formula (2):
[0106] [ka]
[0107] R in formula (2) of the present invention 1 R is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom, and specific examples of the hydrocarbon group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group, a phenyl group, and a benzyl group. 1 A preferred embodiment of R is a methyl group or a hydrogen atom, and more preferably a methyl group. 1 has the same meaning as above.
[0108] In the formula (2) of the present invention, n represents the number of repeating units of the monodisperse polyethylene glycol and is an integer of 3 to 72, preferably an integer of 4 to 48, more preferably an integer of 6 to 36, and particularly preferably an integer of 8 to 24. In addition, n in the formula (2) has the same meaning as above.
[0109] In the present specification, X in formula (2) 2 and Y 2 One is an antibody and the other is a drug.
[0110] W, Z and b in the formula (2) of the present invention have the same meanings as W, Z and b in the above formula (1).
[0111] A in formula (2) of the present invention 2 , B 2 and C 2 are divalent spacers, each consisting of a covalent bond.
[0112] Specifically, A 2 -L 1 -(CH2) m1 -L 7 -, -L 1 -(CH2) m1 -L 8 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 -L 8 -or-L 8 -, preferably -L 1 -(CH2) m1 -L 8 -, -L 1 -(CH2) m1 -L 2 -(CH2) m2 -L 8 -or-L 8 In addition, L in the formula 1 , L 2 , m1 and m2 are as defined above.
[0113] Also, B 2 Ha-CH2-L 9 -, -CH2-L 9 -(CH2) m3 -L 10 -, -CH2-L 9 -(CH2) m3 -L 10 -(CH2) m4 -L 11 -, -CH2-L 12-, -CH2-L 9 -(CH2) m3 -L 12 -or-CH2-L 9 -(CH2) m3 -L 10 -(CH2) m4 -L 12 -, preferably -CH2-L 9 -(CH2) m3 -L 10 -, -CH2-L 9 -(CH2) m3 -L 12 -or-CH2-L 9 -(CH2) m3 -L 10 -(CH2) m4 -L 12 -, more preferably -CH2-L 9 -(CH2) m3 -L 10 -or-CH2-L 9 -(CH2) m3 -L 12 In the formula, m3 and m4 have the same meanings as defined above.
[0114] In the above formula, L 7 , L 9 , L 10 and L 11 are each independently an ether bond, a urethane bond, an amide bond, a secondary amino group, or a carbonyl group.
[0115] In addition, L 7 and L 11 is a bond formed with W represented by the formula (1), each of which is independently preferably an amide bond or a secondary amino group; L 9 is preferably an ether bond or a urethane bond, and L 10 is preferably a urethane bond, an amide bond or a secondary amino group.
[0116] In addition, L in the above formula 8 and L 12When a3=0 or a4=0, X of the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) is 1 or Y 1 Functional groups contained in and X 2 or Y 2 Specifically, the bond is an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing these, or a single bond.
[0117] Furthermore, C 2 is a heterobifunctional monodisperse polyethylene glycol represented by the formula (1) in the presence of a peptide linker represented by W. 1 or Y 1 and a functional group present in an antibody or drug, and specifically, it is an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing these.
[0118] In the present invention, a3 and a4 in formula (2) are each -W-(Z) b -C 2 - indicates the presence or absence of a spacer site, and X 2 is a drug, a3=1 and a4=0, and Y 2 When is a drug, a3=0 and a4=1.
[0119] In a specific embodiment of the present invention, the antibody-drug conjugate (ADC) is a compound represented by the following formula (I) or a salt thereof, in which Ab represents an antibody, D represents a drug, L represents a linker consisting of a heterobifunctional monodisperse polyethylene glycol represented by formula (1) above, and k represents the number of linker-drug conjugate (DL) units bound to the antibody.
[0120] [ka]
[0121] Specific embodiments of the binding modes of the antibody (Ab), drug (D), linker (L) and linker-drug conjugate (DL) of the present invention, as well as the number of drugs bound to the ADC, are described below.
[0122] As used herein, the term "antibody" is used in its broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller, K. et al. J. Immunol. 2003, 170, 4854-4861).
[0123] Antibodies can be murine, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens (Janeway, C.; Travers, P.; Walport, M.; Shlomchik, M. Immunobiology, 5th ed.; Garlan Publishing: New York, 2001). Target antigens typically have multiple binding sites (also called epitopes) that are recognized by CDRs on multiple antibodies. Antibodies that specifically bind to different epitopes have different structures. Thus, a given antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules (i.e., molecules that contain an antigen binding site that immunospecifically binds to the antigen or portion thereof of interest). Such targets include, but are not limited to, cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. The immunoglobulins disclosed herein can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass of immunoglobulin molecule. The immunoglobulins can be from any species. However, in one embodiment, the immunoglobulins are of human, murine, or rabbit origin.
[0124] Polyclonal antibodies are heterogeneous populations of antibody molecules, such as those derived from the serum of immunized animals. Polyclonal antibodies against target antigens may be produced using various procedures known in the art. For example, to produce polyclonal antibodies, various host animals, including but not limited to rabbits, mice, rats and guinea pigs, may be immunized with target antigen or its derivatives by injection. Depending on the host species, various adjuvants may be used to increase the immune response, including but not limited to Freund's (complete and incomplete) adjuvants, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmett-Guerin) and Corynebacteriumu parvum. Such adjuvants are also known in the art.
[0125] Monoclonal antibodies are homogeneous populations of antibodies against a particular antigenic determinant (e.g., cellular antigens (cancer or autoimmune cell antigens), viral antigens, microbial antigens, proteins, peptides, carbohydrates, chemicals, nucleic acids, or antigen-binding fragments thereof). Monoclonal antibodies (mAbs) against an antigen of interest may be prepared using any technique known in the art. These include, but are not limited to, the hybridoma technique first described by Kohler, G; Milstein, C. Nature 1975, 256, 495-497), the human B-cell hybridoma technique (Kozbor, D. et al. Immunol. Today 1983, 4, 72-79), and the EBV-hybridoma technique (Cole, SPC et al. Monoclonal Antibodies and Cancer Therapy; Alan R. Liss: New York, 1985, pp. 77-96). Such antibodies may be of any immunoglobulin class, including IgG, IgM, IgE, IgA and IgD, and any subclass thereof. Hybridomas producing monoclonal antibodies in the present invention may be cultivated in vitro or in vivo.
[0126] Monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies, and antibody fragments. Human monoclonal antibodies may be produced by any of the numerous techniques known in the art (see, for example, Teng, NN et al. Proc.Natl.Acad.Sci.USA.1983, 80, 7308-7312; Kozbor, D. et al. Immunology Today 1983, 4, 72-79; Olsson, L. et al. Meth. Enzymol. 1982, 92, 3-16, and U.S. Pat. Nos. 5,939,598 and 5,770,429). Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, can be produced using standard recombinant DNA techniques known in the art (see, for example, U.S. Pat. Nos. 4,816,567 and 4,816,397).
[0127] Antibody resurfacing processes can also reduce the immunogenicity of antibodies (see U.S. Pat. No. 5,225,539, European Patent Nos. 0239400, 0519596, 0592106).
[0128] In one embodiment of the present invention, the antibody may be a bispecific antibody. Methods for making bispecific antibodies are known in the art. A conventional method for making full-length bispecific antibodies utilizes the co-expression of two immunoglobulin heavy-light chain pairs, where the two chains have different specificities (see Milstein, C et al. Nature 1983, 305, 537-539). Alternatively, bispecific antibodies can be made by fusing antibody variable domains with the desired binding specificities (antibody-antigen binding sites) to immunoglobulin constant domain sequences.
[0129] Other useful antibodies include fragments of antibodies, including, but not limited to, F(ab')2 fragments, Fab' fragments, Fab fragments, Fvs, single chain antibodies (SCAs) (e.g., as described in U.S. Pat. No. 4,946,778; Bird, RE et al. Science 1988, 242, 423-442; Huston, JS et al. Proc. Natl. Acad. Sot USA 1988, 85, 5879-5883; and Ward, ES et al. Nature 1989, 334, 544-554), scFv, sc-Fv-Fc, FvdsFv, minibodies, diabodies, triabodies, tetrabodies, and any other molecules that contain CDRs and have the same specificity as an antibody, such as domain antibodies.
[0130] In a preferred embodiment of the present invention, known antibodies for the treatment or prevention of cancer may be used. Any target protein can be targeted by the antibody, including any target protein whose expression correlates with expression on cells of cancer, cell proliferation disorder or tumor.
[0131] In a preferred embodiment of the invention, the antibodies are useful for the treatment of cancer. Examples of antibodies that can be used for the treatment of cancer include Rituxan® (Genentech), a chimeric anti-CD20 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma, Ovalex (Altalex), a murine antibody for the treatment of ovarian cancer, Panorex (GlaxoWellcome), a murine IgG2a antibody for the treatment of colorectal cancer, Cetuximab Erbitux (Immuclone Systems), an anti-EGFR IgG chimeric antibody for the treatment of epidermal growth factor positive cancers such as head and neck cancer, Vitaxin (MedImmune), a humanized antibody for the treatment of sarcoma, Campas I / H (Leucocyte), a humanized IgG1 antibody for the treatment of chronic lymphocytic leukemia (CLL), Smart M195 (Protein Design Labs), a humanized anti-CD33 IgG antibody for the treatment of acute myeloid leukemia (AML), and humanized anti-CD22 (Protein Design Labs), a ... These include, but are not limited to, Lymphoside (Immunomedics), an IgG antibody; Smart ID10 (Protein Design Labs), a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma; Oncolym (Techniclone), a radiolabeled murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma; Alloimmune (Biotransplant), a humanized anti-CD2 mAb for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma; Avastin (Genentech), a humanized anti-VEGF antibody for the treatment of lung and colorectal cancer; Epratuzamab (Immunomedics and Amgen), an anti-CD22 antibody for the treatment of non-Hodgkin's lymphoma; and Seaside (Immunomedics), a humanized anti-CEA antibody for the treatment of colorectal cancer.
[0132] In a preferred embodiment of the invention, the antibodies are directed against the following antigens: CA125, CA15-3, CA19-9, L6, Lewis Y, Lewis X, alpha-fetoprotein, CA242, placental alkaline phosphatase, prostate-specific membrane antigen, EphB2, TMEFF2, prostatic acid phosphatase, epidermal growth factor, MAGE-1, MAGE-2, MAGE-3, MAGE-4, anti-transferrin receptor, p97, MUC1-KLH, CEA, gp100, MART1, prostate-specific antigen, IL-2 receptor, CD20, CD52, CD33, CD22, human chorionic gonadotropin, CD38, CD40, mucin, P21, MPG and Neu oncogene product. Some specific useful antibodies include mAbs against the CD40 antigen, such as BR96 mAb (Trail, PA et al. Science 1993, 261, 212-215), BR64 (Trail, PA et al. Cancer Research 1997, 57, 100-105), S2C6 mAb (Francisco, JA et al. Cancer Res. 2000, 60, 3225-3231), or other anti-CD40 antibodies as disclosed in U.S. Patent Application Publication Nos. 2003 / 0211100 and 2002 / 0142358, mAbs against the CD70 antigen, such as 1F6 mAb and 2F2 mAb, and AC10 (Bowen, MA et al. J. Immunol. 1993, 151, 5896-5906; Wahl, AF et al. Cancer Research 1997, 57, 100-105), S2C6 mAb (Francisco, JA et al. Cancer Res. 2000, 60, 3225-3231). Res. 2002, 62(13), 3736-42) or MDX-0060 (U.S. Patent Application Publication No. 2004 / 0006215).
[0133] Drugs that can be used in the present invention include chemotherapeutic agents. Chemotherapeutic agents are compounds useful in the treatment of cancer. Examples of chemotherapeutic agents include: alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, altreta, and cyclophosphamide; These include altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); camptothecin (including the synthetic analogue topotecan); bryostatin (bryostatin); callystatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin and bizelesin); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including its synthetic analogs KW-2189 and CBI-TMI); eleutherobin; pancratistatin; sarcodictyin; spongistatin;Nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembicine, phenesterine, prednimustine, trophosphamide, trofosfamide, uracil mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, such as enediyne antibiotics (such as calicheamicin, especially calicheamicin gamma 1 and calicheamicin theta I, e.g. Angew See Chem Intl. Ed. Engl. 33:183-186 (1994); including dynemicin, dynemicin A; esperamicin; and neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, authramicin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin;chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, sate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as frolinic acid; aceglatone;Aldophosphamide glycoside; Aminolevulinic acid; Amsacrine; Bestrabucil; Bisantrene; Edatraxate; Defofamine; Demecolcine; Diaziquone; Elfomithine; Elliptinium acetate; Epothilone; Etoglucid; Gallium nitrate; Hydroxyurea; Lentinan; Lonidamine; Maytansinoids, e.g. maytansine (maytansine) and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes, (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa;Taxoids, such as paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomithine (DMFO); retinoic acid; capecitabine; and pharma-ceutical acceptable salts, acids, or derivatives of any of the above. Also included in this definition are antihormonal agents that act to modulate or inhibit the action of hormones on tumors, such as: antiestrogens, including, for example, tamoxifen, raloxifene, 4(5)-imidazoles that inhibit aromatase, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and antiandrogens, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin;siRNA and pharma- ceutically acceptable salts, acids, or derivatives of any of the above. Other chemotherapeutic agents that can be used with the present invention are disclosed in U.S. Patent Application Publication No. 2008 / 0171040 or U.S. Patent Application Publication No. 2008 / 0305044, which are incorporated by reference in their entirety.
[0134] In a preferred embodiment of the present invention, the chemotherapeutic agent is a small molecule drug. Small molecule drugs preferably have a molecular weight of 100-1500, more preferably 120-1200, and even more preferably 200-1000. The term generally refers to organic, inorganic, or organometallic compounds, typically having a molecular weight of less than about 1000. Small molecule drugs of the present invention also include oligopeptides and other biomolecules having a molecular weight of less than about 1000. Small molecule drugs have been well characterized in the art, for example, in WO 05 / 058367, EP 85901495 and EP 8590319, among others, and in U.S. Pat. No. 4,956,303, which are incorporated by reference in their entirety.
[0135] The preferred small molecule drugs of the present invention are small molecule drugs that can be linked to antibodies. The present invention includes known drugs and drugs that may become known. Particularly preferred small molecule drugs include cytotoxic drugs.
[0136] Preferred cytotoxic drugs are maytansinoids, CC-1065 analogs, morpholinos, doxorubicins, taxanes, cryptophycins, epothilones, calicheamicins, auristatins, and pyrrolobenzodiazepine dimers.
[0137] The antibody-drug conjugate comprising the heterobifunctional monodisperse polyethylene glycol represented by formula (2) of the present invention can be prepared by binding an antibody to a drug using the heterobifunctional monodisperse polyethylene glycol represented by formula (1). The antibody-drug conjugate represented by formula (2) may be prepared by binding a drug to the heterobifunctional monodisperse polyethylene glycol represented by formula (1) and then binding an antibody, or by binding an antibody to the heterobifunctional monodisperse polyethylene glycol represented by formula (1) and then binding a drug. In addition, purification may be performed after binding either the antibody or the drug, or after binding both the antibody and the drug.
[0138] The compound in which a drug is bound to the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) can be purified by purification means such as column chromatography, extraction, recrystallization, adsorbent treatment, reprecipitation, supercritical extraction, etc. In addition, the compound in which an antibody is bound to the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) and the antibody-drug complex in which both an antibody and a drug are bound can be purified by purification means such as column chromatography, extraction, adsorbent treatment, etc.
[0139] Linker-drug conjugates in which the heterobifunctional monodisperse polyethylene glycol of formula (1) is attached to a drug can be prepared using standard conjugation techniques known in the art (see, for example, U.S. Patent Application Publication Nos. 8,163,888, 7,659,241, 7,498,298, and WO 2011 / 023883 and WO 2005 / 112919).
[0140] The conjugate of the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or the linker-drug conjugate consisting of the linker and a drug and an antibody is preferably a conjugate of the atomic group X 1 or Y 1The conjugated antibody can be synthesized under conditions in which the functional group contained in reacts with the functional group in the antibody to form a covalent bond. In addition, the chemical reaction used generally does not alter the integrity of the antibody, for example, the antibody's ability to bind to a target. Preferably, the binding characteristics of the conjugated antibody are similar to those of the unconjugated antibody.
[0141] A conjugate in which the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or a linker-drug conjugate consisting of the linker and a drug is bound to an antibody can be prepared using chemical reactions and techniques known in the art (e.g., Arnon, R. et al.; Monoclonal antibodies as carriers for immunotargeting of drugs; Monoclonal antibodies for cancer detection and therapy. Academic Press; Baldwin, RW et al. eds.; London, 1985, 367-382; Hellstrom, KE et al.; Antibodies for drug delivery.; Controlled Drug Delivery; Robinson, JR et al. eds.; Marcel Dekker, Inc.; New York; 1987, 623-653; Thorpe, PE et al. Monoclonal antibodies, 1985, 84: 475-506; Order, SE; Analysis, results, and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy; (see "Monoclonal antibodies for cancer detection and therapy. Academic Press; Baldwin, RW et al. eds.: London, 1985," "Thorpe, PE et al. Immunol Rev. 1982, 62:119-158," and WO 89 / 12624).
[0142] The heterobifunctional monodisperse polyethylene glycol represented by formula (1) or the linker-drug conjugate consisting of the linker and a drug can be bound to the side chain of an amino acid residue of an antibody. For example, the primary amino group of an available lysine residue, or the free thiol group of an available cysteine residue. In one embodiment of the present invention, the bond formed by reaction with an antibody is a bond formed with an amino group of the antibody, for example, an amide bond, a thioether bond, and a thiourea bond, and preferably an amide bond. In addition, in certain embodiments, the bond formed by reaction with an antibody is a bond formed with a thiol group of the antibody, for example, an amide bond, a maleimide-thiol bond, a thioether bond, and a thiourea bond, and preferably a maleimide-thiol bond and a thioether bond.
[0143] In a preferred embodiment of the present invention, the bond between the heterobifunctional monodisperse polyethylene glycol or linker-drug conjugate of the present invention and the antibody is a maleimide-thiol bond or a thioether bond generated by reaction with interchain cysteine residues of the antibody. In order to obtain a more homogeneous ADC, it is desirable to bind an average of eight drugs per antibody by reacting with cysteine residues generated by reducing four pairs of interchain disulfide bonds of the antibody.
[0144] Functional groups for linking the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or a linker-drug conjugate consisting of the linker and a drug to the primary amino group of an available lysine residue are known and include, but are not limited to, an NHS-ester group, an N-succinimidyl carbonate group, and a p-nitrophenyl carbonate group.
[0145] Functional groups for linking the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or a linker-drug conjugate consisting of the linker and a drug to the free thiol group of an available cysteine residue are known and include, but are not limited to, an α-haloacetyl group and a maleimide group.
[0146] However, the functional group of an antibody that reacts with the heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or a linker-drug conjugate consisting of the linker and a drug is not limited to the side chain group of a naturally occurring amino acid, and can be converted to another useful functional group by reacting an appropriate small molecule with the amino acid side chain of the antibody. For example, an amino acid side chain such as an amino group can be converted to another useful functional group such as a hydroxy group by reacting an appropriate small molecule with the amino group.
[0147] As for the functional group of an antibody for conjugation, an amino acid may be introduced at any position of the antibody by genetic engineering, and the amino acid to be introduced may be either natural or non-natural. Genetic engineering techniques for introducing amino acid residues into an antibody are described, for example, in "Axup, JY et al. Proc Natl Acad Sci. 2012, 109:16101-16106" and "Tian, F. et al. Proc Natl Acad Sci. 2014, 111:1766-1771".
[0148] The heterobifunctional monodisperse polyethylene glycol represented by the formula (1) or a linker-drug conjugate consisting of the linker and a drug may be bound to an antibody in a site-nonspecific or site-specific manner, but site-specific conjugation is preferred.
[0149] The antibody-drug conjugates (ADCs) comprising the heterobifunctional monodisperse polyethylene glycol of formula (2) of the present invention can be prepared by standard methods similar to those described in Hamblett, KJ et al. Clin. Cancer Res. 2004, 10:7063-7070, Doronina, SO et al. Nat Biotechnol. 2003, 21:778-784, Francisco, JA et al. Blood, 2003, 102:1458-1465, Chari, RVJ et al. Cancer Res. 1992, 52:127-131, and Tumey, LN et al. ACS Med. Chem. Lett. 2016, 7:977-982. For example, an ADC having eight drugs per antibody, in which the linker-drug conjugate of the present invention is bound to the interchain cysteine residue of the antibody, can be partially reduced with an excess of a reducing agent such as dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP) at 37°C for 1 hour, and then an excess of a linker-drug conjugate consisting of a heterobifunctional monodisperse polyethylene glycol represented by formula (1) and a drug, for example 15 equivalents, is added at 20°C for 1 hour, and then an excess of N-acetyl-L-cysteine, for example 50 equivalents, is added to quench the reaction. The resulting ADC mixture can also be purified by gel filtration chromatography using NAP®-5 equilibrated with PBS to remove desalted and unreacted linker-drug conjugates, and can be further purified by size exclusion chromatography. The resulting ADC can then be sterile filtered, for example, using a 0.2 μm filter, and lyophilized for storage.
[0150] The number of drugs per antibody in an ADC can be determined by methods known to those of skill in the art, such as, for example, UV / Vis spectroscopy, mass spectrometry, ELISA, electrophoresis, HPLC, and combinations thereof (e.g., as described in Chen, J. et al. Anal. Chem. 2013, 85:1699-1704, Valliere-Douglass, JF et al. Anal. Chem. 2012, 84:2843-2849, Birdsall, RE et al. mABs, 2015, 7:1036-1044, and Zhao, RY et al. J. Med. Chem. 2011, 54:3606-3623). In one embodiment, the average number of drugs per antibody in an ADC can be calculated by UV / Vis spectroscopy. Specifically, it can be calculated by measuring the UV absorbance of an aqueous solution of the antibody-drug conjugate at two different wavelengths, for example, 280 nm and 495 nm, and then performing the following calculation. Since the total absorbance at a certain wavelength is equal to the sum of the absorbance of all absorbing chemical species present in the system [additivity of absorbance], if it is assumed that there is no change in the molar absorption coefficients of the antibody and drug before and after the conjugation reaction of the antibody and drug, the antibody concentration and drug concentration in the antibody-drug conjugate are expressed by the following relational equation. A280=εD,280CD+εA,280CA Formula (i) A495=εD,495CD+εA,495CA Formula (ii) DAR=CD / CA Equation (iii) A280 indicates the absorbance of the antibody-drug complex aqueous solution at 280 nm, A495 indicates the absorbance of the antibody-drug complex aqueous solution at 495 nm, εA,280 indicates the molar absorption coefficient of the antibody at 280 nm, εA,495 indicates the molar absorption coefficient of the antibody at 495 nm, εD,280 indicates the molar absorption coefficient of the linker-drug conjugate at 280 nm, εD,495 indicates the molar absorption coefficient of the linker-drug conjugate at 495 nm, CA indicates the antibody concentration in the antibody-drug complex, and CD indicates the drug concentration in the antibody-drug complex. Estimates are used for εA,280 and εA,495, and εA,495 is usually 0. εD,280 and εD,495 can be obtained by measuring the absorbance of a solution in which the linker-drug conjugate used is dissolved at an arbitrary molar concentration, and using the Beer-Lambert law (absorbance = molar concentration × molar extinction coefficient × cell path length). CA and CD can be calculated by measuring A280 and A495 of the antibody-drug complex solution, substituting these values into equations (i) and (ii) and solving the simultaneous equations. Furthermore, the average number of drugs bound per antibody can be calculated by dividing CD by CA.
[0151] The number of drugs bound to an antibody via the heterobifunctional monodisperse polyethylene glycol represented by formula (1) of the present invention, represented by k in the formula (I), is defined, for example, by the average number of drugs per antibody. In the reaction between the heterobifunctional monodisperse polyethylene glycol represented by formula (1) of the present invention or the linker-drug conjugate and an antibody, the number of bonds can be determined by the number of reactive sites on the antibody to which the linker or linker-drug conjugate reacts. Not all reactive sites on the antibody need to be blocked, and conjugates having different numbers of drugs bound to the antibody may be mixed in the prepared ADC. However, by controlling or purifying the reactive sites, a conjugate in which the number of drugs bound to the antibody is single can also be obtained. Therefore, the number of drugs bound to one antibody may be either the average value of the distribution or a single value, but a single value is preferable because the physical properties of the ADC are stabilized when there is little or no distribution. For this reason, k in the formula (I) represents a number with a distribution that is not an integer or an integer.
[0152] In an embodiment of the present invention, the number of drugs bound to one antibody is preferably 1 to 20, more preferably 2 to 16, even more preferably 3 to 12, particularly preferably 4 to 8, and most preferably 8.
[0153] The heterobifunctional monodisperse polyethylene glycol of the present invention is required to have the ability to specifically degrade in cells and effectively sustainedly release drugs. In order to properly evaluate the performance, for example, the following test can be carried out to evaluate the degradability of the heterobifunctional monodisperse polyethylene glycol in cells and the activity of the drug bound to the linker in cells.
[0154] There is no particular limitation on the test method for evaluating the degradability of the heterobifunctional monodisperse polyethylene glycol by intracellular enzymes, and examples thereof include a test for confirming the decomposition of a model compound or drug to which the linker is bound using a lysosomal enzyme, which is an intracellular enzyme. Specifically, if the lysosomal enzyme is cathepsin B, a solution containing a model compound or drug to which the heterobifunctional monodisperse polyethylene glycol is bound is added to a cathepsin B / DTT solution prepared by adding DTT, a reducing agent, to cathepsin B, and after incubation at 37°C, HPLC measurement of the sampled solution is performed, and the degradability can be confirmed by comparing the charts before and after the test. Furthermore, if there is a new peak, the linker cleavage site and the structure of the released model compound or drug can be confirmed by checking the mass chromatogram.
[0155] There are no particular limitations on the model compound used in the test. However, when the heterobifunctional monodisperse polyethylene glycol has a maleimide group as a functional group, the cysteine residue of cathepsin B reacts with the maleimide group to inhibit the enzyme reaction. Therefore, it is preferable to use a model compound that reacts with the maleimide group, such as a compound having a thiol group, specifically glutathione.
[0156] The drug used in the test is not particularly limited as long as it is one of the drugs listed above, but examples thereof include drugs having an amino group, specifically, doxorubicin.
[0157] Furthermore, there is no particular limitation on the test method for evaluating the intracellular pharmacological activity of the drug-linker compound bound to the heterobifunctional monodisperse polyethylene glycol, and examples thereof include a cytotoxicity test in which cells are cultured in a medium containing the drug-linker compound and the cell viability is calculated.
[0158] If the peptide linker introduced into the heterobifunctional monodisperse polyethylene glycol of the present invention is not degraded in cells, the bond with the drug is not degraded in cells, and the activity of the drug may be reduced. Since the higher the cell viability, the lower the activity of the drug. The cell viability is calculated by this test, and compared with the cell viability of a control drug-linker compound that does not contain a peptide linker, thereby evaluating the activity of the drug in cells by using the heterobifunctional monodisperse polyethylene glycol of the present invention.
[0159] There are no particular limitations on the cells and medium used here, but specifically, the drug-linker compound is dissolved in RPMI-1640 medium, HeLa cells are cultured at 37°C, and a color reaction is performed using a live cell count measurement kit, followed by measuring the absorbance, which allows the cell viability to be calculated. The cell viability is calculated by dividing the absorbance of the sample, after subtracting the absorbance of the blank, by the absorbance of only the cells not containing the sample.
[0160] In addition, the oligopeptide introduced into the heterobifunctional monodisperse polyethylene glycol of the present invention is required to have a more hydrophilic property that does not interfere with the shielding effect of the linker on the hydrophobic drug. In order to appropriately evaluate the performance, for example, the following test can be performed to evaluate the hydrophilicity of the heterobifunctional monodisperse polyethylene glycol.
[0161] The test method for evaluating the hydrophilicity of the peptide in the heterobifunctional monodisperse polyethylene glycol is not particularly limited, and may be evaluated by methods known to those skilled in the art, such as size exclusion chromatography (SEC), ion exchange chromatography (IEC), reversed phase (RP) chromatography, and HPLC using hydrophobic interaction chromatography (HIC) (see, for example, Mant, CT et al. Methods Mol Biol. 2007, 386:3-55). In an exemplary embodiment, the hydrophilicity of the peptide can be evaluated by measuring the target compound under the same conditions using reversed phase HPLC and comparing the retention times of the peak tops. In the case of reversed phase HPLC, the higher the hydrophilicity of the target compound, the shorter the retention time it is detected. EXAMPLES
[0162] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.
[0163] 1 For H-NMR analysis, JNM-ECP400 or JNM-ECA600 manufactured by JEOL Datum Co., Ltd. was used. A φ5 mm tube was used for the measurement, and tetramethylsilane (TMS) was used as the internal standard substance when the deuterated solvent was CDCl3, CD2Cl2 or DMSO-d6.
[0164] Example 1: Synthesis of Compound 11 Trishydroxymethylaminomethane (30.3 g, 250 mmol), sodium carbonate (5.30 g, 50 mmol), dehydrated methanol (237 g) and benzonitrile (5.15 g, 50 mmol) were charged into a 500 mL four-neck flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube and a cooling tube, and the reaction was carried out at 65°C for 24 hours. After filtration and distillation of the solvent under reduced pressure, isopropyl alcohol and dichloromethane were added to dissolve the residue, and the mixture was washed with 10 wt% saline. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled under reduced pressure. The residue was dissolved in tetrahydrofuran, crystallized by adding hexane, and filtered to obtain the compound of formula (11). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 3.06(2H, brs, -O H ), 3.65-3.81(4H, dd, >C(C H 2OH)2), 4.38(2H, s, -CNO-C H 2-), 7.32-7.83(5H, m, arom. H )
[0165] [ka]
[0166] Example 2: Synthesis of Compound 12 Dodecaethylene glycol monomethyl ether (10.4 g, 18.5 mmol), toluene (52.0 g), triethylamine (2.44 g, 24.1 mmol), and methanesulfonyl chloride (2.34 g, 20.4 mmol) were charged into a 100 mL three-neck flask equipped with a thermometer, nitrogen inlet, stirrer, Dean-Stark tube, and condenser, and the reaction was carried out at 40°C for 3 hours. After dilution with dichloromethane, the mixture was washed with water, and the organic layer was dried over anhydrous magnesium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain the compound of formula (12). 1H-NMR (CDCl3, internal standard TMS); δ(ppm): 3.08(3H, s, -O-SO2-C H 3), 3.38(3H, s, -OC H 3), 3.45-3.85(46H, m, CH3-O-(C H 2C H 2O) 11 -C H 2CH2-O-SO2-CH3), 4.38(2H, m, -C H 2-O-SO2-CH3)
[0167] [ka]
[0168] Example 3: Synthesis of Compound 13 A 50 mL three-neck flask equipped with a thermometer, nitrogen inlet, stirrer, Dean-Stark tube, and condenser was charged with the compound of formula (11) (0.21 g, 1.01 mmol), dehydrated tetrahydrofuran (7.70 g), the compound of formula (12) (2.46 g, 3.84 mmol), and 1M potassium tert-butoxide / tetrahydrofuran solution (3.72 g, 4.04 mmol), and the reaction was carried out at 50°C for 4 hours. Dichloromethane and 25 wt% saline were added and washed with water, and the organic layer was dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain the compound of formula (13). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 3.38(6H, s, -OC H 3), 3.40-3.75(100H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CNO-C H 2-), 4.36(2H, s, -CNO-C H 2-), 7.37-7.94(5H, m, arom.H )
[0169] [ka]
[0170] Example 4: Synthesis of Compound 14 In a 100 mL three-neck flask equipped with a thermometer, nitrogen inlet tube, stirrer, Dean-Stark tube, and condenser, the compound of formula (13) (1.13 g, 0.877 mmol) and distilled water (31.1 g) were added and dissolved. After adjusting the pH to 1.5 by adding 85% phosphoric acid (0.43 ml), the reaction was carried out at 50°C for 3 hours. Next, 400 g / L aqueous sodium hydroxide solution (5.58 ml) was added while cooling, and the reaction was carried out at 50°C for 6 hours. Subsequently, 6N hydrochloric acid was added to adjust the pH to 2.0, and then toluene and chloroform were added for washing. Sodium chloride was added to the aqueous layer to make it 25 wt% saline, and the pH was adjusted to 12.5 using 400 g / L aqueous sodium hydroxide solution. Extraction was carried out using toluene and dried over anhydrous sodium sulfate. After filtration, the solvent was distilled off under reduced pressure to obtain the compound of formula (14). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 3.08(1H, brs, -O H ), 3.38(6H, s, -OC H 3), 3.40-3.80(102H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNH2-C H 2-OH)
[0171] [ka]
[0172] Example 5: Synthesis of Compound 15 In a 50 mL three-neck flask equipped with a thermometer, a nitrogen inlet tube, a stirrer, a Dean-Stark tube, and a condenser, the compound of formula (14) (1.80 g, 1.49 mmol), L-phenylalanine-glycine (Fmoc-Phe-Gly) (0.862 g, 1.94 mmol, Watanabe Chemical Industry Co., Ltd.) in which the N-terminus is protected with a 9-fluorenylmethyloxycarbonyl group (Fmoc group), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM) (0.670 g, 1.94 mmol), acetonitrile (18.0 g), and N,N-diisopropylethylamine (0.263 g, 2.04 mmol) were charged, and the reaction was carried out at 25°C for 7 hours. After adding 5wt% sodium dihydrogen phosphate aqueous solution (10.8 g), acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene and hexane. Extraction was performed using toluene and chloroform, followed by washing with 5wt% sodium dihydrogen phosphate aqueous solution and 5wt% disodium hydrogen phosphate aqueous solution containing 20wt% sodium chloride. The organic layer was further washed with 20wt% saline, dried over anhydrous magnesium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (15). 1 H-NMR (CD2Cl2, internal standard TMS); δ(ppm): 2.99-3.26(2H, m, -CH-C H 2-phenyl), 3.38(6H, s, -OC H 3), 3.45-3.90(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -C H -CH2-phenyl, >CCH2-NHCO-C H 2-NHCO-CH-, -NH-C(O)OC H 2-Fmoc(1H)) 3.94-4.46(6H, m, >CNH-C H 2-OH, >CCH2-NHCO-CH2-N H CO-CH-, >CNH-CH2-O H , -NH-C(O)OC H2-Fmoc(1H), -NH-C(O)O-CH2- Fmoc(CH) ), 5.63(1H, d, -N H -C(O)O-CH2-Fmoc), 6.74(1H, brs, >CCH2-N H CO-CH2-), 7.09-7.76(13H, m, arom.H )
[0173] [ka]
[0174] Example 6: Synthesis of Compound 16 The compound of formula (15) (1.80 g, 1.10 mmol), N-phenylmorpholine (0.449 g, 3.85 mmol), p-nitrophenyl chloroformate (0.621 g, 3.08 mmol), and dichloromethane (17.9 g) were added to a 20 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours. After dilution with 6.7 wt% β-alanine aqueous solution (11.8 g), dichloromethane was distilled off under reduced pressure, and 400 g / L sodium hydroxide aqueous solution (0.869 g, 6.60 mmol) was added, and the reaction was carried out at 25°C for 1 hour. After washing the reaction solution with toluene and dichloromethane, sodium chloride was dissolved in the aqueous layer to make 15 wt% saline, and extraction was carried out using dichloromethane. Acetonitrile was added to the organic layer, which was then washed with a 5 wt% aqueous sodium carbonate solution containing 15 wt% sodium chloride, and then washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride. The organic layer was dried over anhydrous sodium sulfate and filtered, after which the solvent was removed under reduced pressure to obtain the compound of formula (16). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.47-2.52(2H, m, >CNH-CH2-OC(O)-NH-CH2-C H 2-COOH), 2.95-3.24(2H, m, -CH-C H 2-phenyl), 3.38(6H, s, -OC H 3), 3.45-3.90(106H, m, >C(C H2O)2-, -O-(C H 2C H 2O) 12 -, -C H -CH2-phenyl, >CCH2-NHCO-C H 2-NHCO-CH-, -NH-C(O)OC H 2-Fmoc(1H), >CNH-CH2-OC(O)-NH-C H 2-CH2-COOH), 3.94-4.55(5H, m, >CNH-C H 2-OC(O)-NH-, -NH-C(O)O-CH2- Fmoc(CH) , >CCH2-NHCO-CH2-N H CO-CH-, -NH-C(O)OC H 2-Fmoc(1H)), 5.72(1H, brs, >CNH-CH2-OC(O)-N H -CH2-CH2-COOH), 5.81(1H, d, -N H -C(O)O-CH2-Fmoc), 6.71(1H, brs, >CCH2-N H CO-CH2-), 7.10-7.80(13H, m, arom.H )
[0175]
change
[0176] (Example 7 Synthesis of Compound 17) The compound of formula (16) (0.935 g, 0.535 mmol), piperidine (0.846 g, 10.7 mmol), and chloroform (6.55 g) were added to a 50 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride, and then the organic layer was diluted with toluene, and extraction was carried out into the aqueous layer using distilled water. The aqueous layer was adjusted to pH 10 using 400 g / L sodium hydroxide aqueous solution, and then washed with toluene, and the aqueous layer pH was adjusted to pH 2.5 using 6 N hydrochloric acid. Salt was dissolved in the aqueous layer to make it 15 wt% saline, and extraction was carried out using chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (17). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.58(2H, m, >CNH-CH2-OC(O)-NH-CH2-C H 2-COOH), 3.15-3.30(1H, m, -NHCO-C H -NH2), 3.38(6H, s, -OC H 3), 3.45-3.90(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CCH2-NHCO-C H 2-NHCO-CH-, -OC(O)-NH-C H 2-CH2-COOH), 4.20-4.50(2H, m, >CNH-C H 2-OC(O)-NH-), 4.59(1H, s, >CCH2-NHCO-CH2-N H CO-CH-NH2), 6.18(1H, brs, -OC(O)-N H -CH2-CH2-COOH), 6.65(1H, brs, >CCH2-N H CO-CH2-), 7.20-7.50(5H, m, arom.H ), 8.77(2H, s, -CH-N H 2)
[0177] [ka]
[0178] Example 8: Synthesis of Compound 18 The compound of formula (17) (0.703 g, 0.450 mmol), 4-(N-maleimidomethyl)cyclohexane-1-carboxylate N-succinimidyl (0.181 g, 0.540 mmol), triethylamine (0.105 g, 1.04 mmol), 2,6-di-tert-butyl-p-cresol (0.21 mg), and chloroform (13.4 g) were added to a 30 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 13 hours under light shielding. The reaction solution was washed with 0.2M citrate phosphate buffer (pH 2.4) containing 20 wt% sodium chloride, the organic layer was concentrated, and the residue was dissolved in 0.2M citrate phosphate buffer (pH 3.0). The aqueous layer was washed with toluene, and then extracted into the organic layer using toluene and chloroform. The organic layer was washed with 20 wt % saline, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (18). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 0.89-2.09(10H, m, - cyclohexyl -), 2.54(2H, brs, -OC(O)-NH-CH2-C H 2-COOH), 2.93-3.20(2H, m, -cyclohexyl-C H 2-maleimide), 3.38(6H, s, -OC H 3), 3.33-3.95(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CCH2-NHCO-C H 2-NHCO-CH-, -OC(O)-NH-C H 2-CH2-COOH), 4.28-4.45(2H, m, >CNH-C H2-OC(O)-NH-), 4.74-4.80(1H, m, -NHCO-C H -NHCO-cyclohexyl-), 5.63(1H, brs, -OC(O)-N H -CH2-CH2-COOH), 6.26(1H, d, >CCH2-NHCO-CH2-N H CO-CH-), 6.64(1H, brs, >CCH2-N H CO-CH2-), 6.69(2H, s, - maleimide ), 7.07(1H, brs, -N H CO-cyclohexyl-), 7.16-7.26(5H, m, arom.H )
[0179] [ka]
[0180] Example 9: Synthesis of Compound 19 The compound of formula (18) (0.351 g, 0.201 mmol), N-hydroxysuccinimide (0.058 g, 0.503 mmol), dimethylaminopropylethylcarbodiimide hydrochloride (0.123 g, 0.643 mmol), and chloroform (2.08 g) were added to a 4 ml screw tube containing a stirrer, and the reaction was carried out for 4 hours at 25° C. under a dark condition. The reaction solution was washed with a 5 wt% aqueous solution of sodium dihydrogen phosphate, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (19). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 0.89-2.01(10H, m, - cyclohexyl -), 2.81-2.90(6H, m, >CNH-CH2-OC(O)-NH-CH2-C H 2-COO-, - N-succinimidyl ), 2.90-3.25(2H, m, -cyclohexyl-C H 2-maleimide), 3.38(6H, s, -OC H3), 3.33-3.95(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CCH2-NHCO-C H 2-NHCO-, -OC(O)-NH-C H 2-CH2-COO-), 4.28-4.45(2H, m, >CNH-C H 2-OC(O)-NH-), 4.65-4.70(1H, m, -NHCO-C H -NHCO-cyclohexyl-), 5.84(1H, brs, -OC(O)-N H -CH2-CH2-COOH), 6.16(1H, d, >CCH2-NHCO-CH2-N H CO-CH-), 6.55(1H, brs, >CCH2-N H CO-CH2-), 6.69(2H, s, - maleimide ), 6.91(1H, brs, -N H CO-cyclohexyl-), 7.15-7.28(5H, m, arom.H )
[0181] [ka]
[0182] Example 10: Reaction of Compound 18 with Glutathione A 4 ml screw tube equipped with a stirrer was charged with the compound of formula (18) (1 mg) and an aqueous solution of 10 mM glutathione / 25 mM sodium acetate / 1 mM ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) (1 ml) adjusted to pH 5 with acetic acid, and the mixture was reacted at 25° C. for 3 hours in the dark to obtain an aqueous solution containing the compound of formula (20).
[0183] [ka]
[0184] Example 11 Synthesis of Compound 21 In a 30 ml screw tube containing a stirrer, the compound of formula (14) (0.350 g, 0.290 mmol), L-valine-L-alanine-glycine (Fmoc-Val-Ala-Gly) (0.154 g, 0.363 mmol, manufactured by GenScript) with the N-terminus protected by a 9-fluorenylmethyloxycarbonyl group (Fmoc group), DMT-MM (0.130 g, 0.508 mmol), acetonitrile (3.50 g), and N,N-diisopropylethylamine (0.073 g, 0.566 mmol) were charged and reacted at 25° C. for 13 hours. After adding a 5 wt% aqueous solution of sodium dihydrogen phosphate (4.20 g), the acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene and hexane. After extraction with toluene and chloroform, the mixture was washed with a 5 wt% aqueous solution of sodium dihydrogen phosphate and a 5 wt% aqueous solution of disodium hydrogen phosphate. The organic layer was washed with a 20 wt% aqueous solution of saline, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (21). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm):0.78-0.93(6H, m, >CH-CH(C H 3)2), 1.22(3H, d, >CH-C H 3), 1.93-2.04(1H, m, >CH-C H (CH3)2), 3.24(6H, s, -OC H 3), 3.38-3.76(102H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-C H 2-NHCO-), 3.83-3.94(1H, m, -CH2- Fmoc(CH) ), 4.16-4.42(6H, m, >C H -CH3, >C H -CH(CH3)2, -C H 2-Fmoc, >CNH-C H2-OH), 4.66(1H, t, >CNH-CH2-O H ), 7.09(1H, s, -N H -C(O)O-CH2-Fmoc), 7.28-7.43(5H, m, arom.H , >CN H CO-CH2-NHCO-), 7.70-7.92(4H, m, arom.H ), 8.00-8.11(2H, m, -N H CO-CH-NHCO-CH-, -NHCO-CH-N H CO-CH-)
[0185] [ka]
[0186] Example 12 Synthesis of Compound 22 The compound of formula (21) (0.306 g, 0.185 mmol), N-phenylmorpholine (0.106 g, 0.648 mmol), p-nitrophenyl chloroformate (0.104 g, 0.518 mmol), and dichloromethane (2.40 g) were added to a 6 mL screw tube containing a stirrer, and the reaction was carried out at 25 ° C for 9 hours. After dilution with 6.7 wt % β-alanine aqueous solution (2.00 g), dichloromethane was distilled under reduced pressure, and 400 g / L sodium hydroxide aqueous solution (0.150 g, 1.11 mmol) was added, and the reaction was carried out at 25 ° C for 1 hour. The reaction solution was washed with toluene and dichloromethane, and then extracted with dichloromethane. After washing with 5 wt % sodium carbonate aqueous solution containing 15 wt % salt, it was further washed with 0.2 M hydrochloric acid containing 20 wt % salt. The organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was then distilled off under reduced pressure to obtain the compound of formula (22). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.78-0.92(6H, m, >CH-CH(C H 3)2), 1.22(3H, d, >CH-C H 3), 1.92-2.03(1H, m, >CH-C H(CH3)2), 2.38(2H, t, >CCH2-OC(O)-NH-CH2-C H 2-COOH), 3.12-3.21(2H, m, >CCH2-OC(O)-NH-C H 2-CH2-COOH), 3.24(6H, s, -OC H 3), 3.38-3.78(102H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-C H 2-NHCO-), 3.88(1H, t, -CH2- Fmoc(CH) ), 4.12-4.40(6H, m, >C H -CH3, >C H -CH(CH3)2, -C H 2-Fmoc, >CC H 2-OC(O)-NH-), 7.09-7.28(2H, m, -N H -C(O)O-CH2-Fmoc, >CCH2-OC(O)-N H -), 7.29-7.45(5H, m, arom.H , >CN H CO-CH2-NHCO-), 7.70-7.94(4H, m, arom.H ), 7.96-8.10(2H, m, -N H CO-CH-NHCO-CH-, -NHCO-CH-N H CO-CH-)
[0187]
change
[0188] (Example 13 Synthesis of Compound 23) The compound of formula (22) (0.177 g, 0.100 mmol), piperidine (0.158 g, 2.00 mmol), and chloroform (2.50 g) were added to a 9 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride, and then the organic layer was diluted with toluene, and extracted into the aqueous layer using distilled water. The aqueous layer was adjusted to pH 10 using 400 g / L sodium hydroxide aqueous solution, washed with toluene and chloroform, and the aqueous layer pH was adjusted to pH 2.5 using 6 N hydrochloric acid. Salt was dissolved in the aqueous layer to make it 10 wt% saline, and extraction was carried out using chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (23). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.71-0.92(6H, m, >CH-CH(C H 3)2), 1.13-1.31(3H, d, >CH-C H 3), 1.82-2.04(3H, m, >CH-C H (CH3)2, >CCH2-OC(O)-NH-CH2-C H 2-COOH), 2.87-3.13(3H, m, >CCH2-OC(O)-NH-C H 2-CH2-COOH, >C H -CH(CH3)2), 3.24(6H, s, -OC H 3), 3.40-3.85(102H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-C H 2-NHCO-), 4.03-4.42(3H, m, >C H -CH3, >CC H 2-OC(O)-NH-), 6.64(1H, brs, >CCH2-OC(O)-N H -), 6.95-7.32(3H, m, >CN H CO-CH2-NHCO-, -N H CO-CH-NHCO-CH-, -NHCO-CH-NH CO-CH-)
[0189] [ka]
[0190] Example 14: Synthesis of Compound 24 The compound of formula (23) (0.100 g, 0.0637 mmol), 4-(N-maleimidomethyl)cyclohexane-1-carboxylate N-succinimidyl (0.0788 g, 0.236 mmol), triethylamine (8.4 mg, 0.0828 mmol), 2,6-di-tert-butyl-p-cresol (0.03 mg), and chloroform (1.90 g) were added to a 9 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 17 hours under light shielding. The reaction solution was washed with 0.2 M citrate phosphate buffer (pH 2.4) containing 20 wt% sodium chloride, the organic layer was concentrated, and the residue was dissolved in 0.2 M citrate phosphate buffer (pH 3.0). The aqueous layer was washed with toluene and chloroform, and then extracted into the organic layer using toluene and chloroform. The organic layer was washed with 20 wt % saline, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (24). 1 H-NMR (CD2Cl2, internal standard TMS); δ(ppm): 0.81-1.12(8H, m, >CH-CH(C H 3) 2, - cyclohexyl -), 1.31-1.48(5H, d, >CH-C H 3, - cyclohexyl -), 1.71-2.18(7H, m, >CH-C H (CH3)2, - cyclohexyl -), 2.48-2.63(2H, m, >CCH2-OC(O)-NH-CH2-C H 2-COOH), 3.34(6H, s, -OC H 3), 3.38-3.95(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12-, >CNHCO-C H 2-NHCO-, >CCH2-OC(O)-NH-C H 2-CH2-COOH, -cyclohexyl-C H 2-maleimide), 4.16-4.38(2H, m, >C H -CH3, >C H -CH(CH3)2), 4.42-4.52(2H, m, >CC H 2-OC(O)-NH-), 6.17-6.32(2H, m, >CN H CO-CH2-NHCO-, >CCH2-OC(O)-N H -), 6.50(1H, brs, >CNHCO-CH2-N H CO-CH-), 6.68(2H, s, - maleimide ), 7.20-7.43(2H, m, >CNHCO-CH2-NHCO-CH-N H CO-CH-, -N H CO-cyclohexyl-)
[0191] [ka]
[0192] Example 15: Synthesis of Compound 25 The compound of formula (24) (0.100 g, 0.0566 mmol), N-hydroxysuccinimide (9.8 mg, 0.0849 mmol), dimethylaminopropylethylcarbodiimide hydrochloride (0.0228 g, 0.119 mmol), and chloroform (0.800 g) were added to a 4 ml screw tube containing a stirrer, and the reaction was carried out for 4 hours at 25° C. under a dark condition. The reaction solution was washed with a 5 wt% aqueous solution of sodium dihydrogen phosphate, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (25). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.75-0.97(8H, m, >CH-CH(C H 3) 2, - cyclohexyl-), 1.17-1.33(5H, d, >CH-C H 3, - cyclohexyl -), 1.48-1.75(5H, m, - cyclohexyl -), 1.93-2.02(1H, m, >CH-C H (CH3)2), 2.17-2.27(1H, m, - cyclohexyl -), 2.81(4H, s, - N-succinimidyl ), 2.83-2.88(2H, m, >CCH2-OC(O)-NH-CH2-C H 2-), 3.23(6H, s, -OC H 3), 3.42-3.75(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-C H 2-NHCO-, >CCH2-OC(O)-NH-C H 2-CH2-, -cyclohexyl-C H 2-maleimide), 4.08-4.33(4H, m, >C H -CH3, >C H -CH(CH3)2, >CC H 2-OC(O)-NH-), 7.01(2H, s, - maleimide ), 7.26-7.35(2H, m, >CN H CO-CH2-NHCO-, >CCH2-OC(O)-N H -), 7.62-7.72(1H, m, -N H CO-cyclohexyl-), 7.90-8.05(2H, m, >CNHCO-CH2-N H CO-CH-, >CNHCO-CH2-NHCO-CH-N H CO-CH-)
[0193]
change
[0194] (Example 16 Synthesis of Compound 26) A 50 ml screw tube containing a stirrer was charged with the compound of formula (14) (2.00 g, 1.66 mmol), Fmoc-β-alanine (0.568 g, 1.82 mmol), DMT-MM (0.631 g, 1.82 mmol), acetonitrile (18.0 g), and N,N-diisopropylethylamine (0.279 g, 2.16 mmol), and the reaction was carried out at 25° C. for 2 hours. After adding a 5 wt% aqueous solution of sodium dihydrogen phosphate (12.0 g), the acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene. Thereafter, purification was carried out in the same manner as in Example 5 to obtain the compound of formula (26). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.99-3.26(2H, m, >CCH2-NHCO-C H 2-CH2-NHCO-), 3.38(6H, s, -OC H 3), 3.45-3.90(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNH-C H 2-OH, >CCH2-NHCO-CH2-C H 2-NHCO-), 4.18-4.22(1H, m, >CNH-CH2-O H ), 4.34(1H, t, -NH-C(O)O-CH2- Fmoc(CH) ), 4.40(2H, d, -NH-C(O)OC H 2-Fmoc), 5.75-5.80(1H, m, -N H -C(O)O-CH2-Fmoc), 6.34(1H, brs, >CCH2-N H CO-CH2-), 7.28-7.78(8H, m, arom.H )
[0195] [ka]
[0196] Example 17: Synthesis of Compound 27 The compound of formula (26) (2.00 g, 1.33 mmol), N-phenylmorpholine (0.762 g, 4.00 mmol), p-nitrophenyl chloroformate (0.753 g, 3.20 mmol), and dichloromethane (19.3 g) were added to a 20 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 6 hours. After dilution with 6.7 wt% β-alanine aqueous solution (14.3 g), dichloromethane was distilled off under reduced pressure, and the reaction was carried out at 25°C for 1 hour. After washing the reaction solution with toluene and dichloromethane, sodium chloride was dissolved in the aqueous layer to make 15 wt% saline, and extraction was carried out with dichloromethane. Acetonitrile was added to the organic layer, and the layer was washed with 15 wt% sodium chloride-containing 5 wt% sodium carbonate aqueous solution, and then further washed with 20 wt% sodium chloride-containing 0.2 M hydrochloric acid. The organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was then distilled off under reduced pressure to obtain the compound of formula (27). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.38(2H, brs, -OC(O)-NH-CH2-C H 2-COOH), 2.51(2H, t, >CCH2-NHCO-C H 2-CH2-), 3.38(6H, s, -OC H 3), 3.40-3.90(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CCH2-NHCO-CH2-C H 2-NHCO-, -OC(O)-NH-C H 2-CH2-COOH), 4.19-4.23(1H, m, -NH-C(O)O-CH2- Fmoc(CH) ), 4.45-4.50(4H, m, >CNH-C H 2-OC(O)-NH-, -NH-C(O)OC H 2-Fmoc), 5.56(1H, brs, >CNH-CH2-OC(O)-N H -), 5.93(1H, brs, -N H -C(O)O-CH2-Fmoc), 6.33(1H, brs, >CCH2-NH CO-CH2-), 7.26-7.78(8H, m, arom.H )
[0197] [ka]
[0198] Example 18: Synthesis of Compound 28 A 20 mL screw tube containing a stirrer was charged with the compound of formula (27) (0.500 g, 0.310 mmol), L-phenylalanine-glycine hydrochloride (H-Phe-Gly-pAB hydrochloride) (0.141 g, 0.387 mmol, Watanabe Chemical Industry Co., Ltd.) condensed with p-aminobenzyl alcohol (pAB) at the C-terminus, DMT-MM (0.134 g, 0.387 mmol), acetonitrile (5.00 g), and N,N-diisopropylethylamine (0.092 g, 0.712 mmol), and reacted at 25°C for 3 hours. After adding a 5 wt% aqueous solution of sodium dihydrogen phosphate (3.00 g), the acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene and hexane. Thereafter, purification was performed in the same manner as in Example 5 to obtain a compound of formula (28). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.20-2.45(4H, m, >CCH2-NHCO-C H 2-CH2-, -OC(O)-NH-CH2-C H 2-), 3.38(6H, s, -OC H 3), 2.60-3.80(108H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, CNH-CH2-OC(O)-NH-C H 2-CH2-, >CCH2-NHCO-CH2-C H 2-NHCO-, -CONH-C H 2-CONH-phenyl-CH2-OH), 3.80-4.57(9H, -NH-C(O)OCH 2-Fmoc, -CONH-phenyl-C H 2-OH, -CH2- Fmoc(CH) , -(CH2)2-CON H -CH-CONH-CH2-, -CH2-O H , -(CH2)2-CONH-CH-CON H -CH2-, -(CH2)2-CONH-C H -CONH-CH2-), 4.61(2H, >CNH-C H 2-OC(O)-NH-), 6.02-6.15(2H, m, -N H -C(O)O-CH2-Fmoc, >CNH-CH2-OC(O)-N H -), 6.53(1H, brs, >CCH2-N H CO-CH2-CH2-), 7.11-7.84(17H, m, arom.H ), 8.89(1H, brs, -CON H -phenyl-CH2-OH)
[0199] [ka]
[0200] Example 19: Synthesis of Compound 29 The compound of formula (28) (0.100 g, 0.052 mmol), piperidine (0.082 g, 1.04 mmol), and chloroform (0.700 g) were added to a 6 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride, and then the organic layer was diluted with toluene, and extraction was carried out into the aqueous layer using distilled water. The aqueous layer was adjusted to pH 10 using 400 g / L sodium hydroxide aqueous solution, and then washed with toluene, and the aqueous layer pH was adjusted to pH 2.5 using 6 N hydrochloric acid. Salt was dissolved in the aqueous layer to make it 15 wt% saline, and extraction was carried out using chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (29). 1H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.20-2.55(6H, m, >CCH2-NHCO-C H 2-, -OC(O)-NH-CH2-C H 2-, -C H 2-NH2), 3.38(6H, s, -OC H 3), 2.90-3.80(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CNH-CH2-OC(O)-NH-C H 2-CH2-, -CONH-C H 2-CONH-phenyl-CH2-OH), 3.80-4.57(6H, -CONH-phenyl-C H 2-OH, -(CH2)2-CON H -CH-CONH-CH2-, -(CH2)2-CONH-CH-CON H -CH2-, -(CH2)2-CONH-C H -CONH-CH2-, -CH2-O H ), 4.61(2H, >CNH-C H 2-OC(O)-NH-), 6.01(1H, brs, >CNH-CH2-OC(O)-N H -), 6.53(1H, brs, >CCH2-N H CO-CH2-CH2-), 7.20-7.80(9H, m, arom.H ), 8.70(2H, brs, -CH2-N H 2), 8.87(1H, brs, -CON H -phenyl-CH2-OH)
[0201]
change
[0202] (Example 20 Synthesis of Compound 30) The compound of formula (29) (0.100 g, 0.058 mmol), 3-maleimidopropionic acid (0.012 g, 0.072 mmol), DMT-MM (0.020 g, 0.072 mmol), triethylamine (0.013 g, 0.132 mmol), and acetonitrile (1.00 g) were added to a 6 ml screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours under light-shielded conditions. After adding 0.2 M citrate phosphate buffer (pH 3.0) (0.600 g), acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene. Extraction was carried out using toluene and chloroform, and then washing was carried out using 0.2 M citrate phosphate buffer (pH 2.4) containing 20 wt% sodium chloride, and 0.2 M citrate phosphate buffer (pH 6.5) containing 20 wt% sodium chloride. The organic layer was washed with 20 wt % saline, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (30). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm):2.13-2.57(6H, m, >CCH2-NHCO-C H 2-, -OC(O)-NH-CH2-C H 2-, -NHCO-C H 2-CH2-maleimide), 3.38(6H, s, -OC H 3), 2.90-3.80(111H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CNH-CH2-OC(O)-NH-C H 2-CH2-, -CONH-C H 2-CONH-phenyl-CH2-OH, -C H 2-maleimide, >CCH2-NHCO-CH2-C H 2-NHCO-, -C H -CH2-phenyl), 3.80-4.57(6H, -CONH-phenyl-C H 2-OH, -(CH2)2-CON H-CH-CONH-CH2-, -(CH2)2-CONH-CH-CON H -CH2-, -(CH2)2-CONH-C H -CONH-CH2-, -CH2-O H ), 4.61(2H, >CNH-C H 2-OC(O)-NH-), 6.01(1H, brs, >CNH-CH2-OC(O)-N H -), 6.53(1H, brs, >CCH2-N H CO-CH2-CH2-), 6.69(2H, s, - maleimide ), 7.20-7.80(9H, m, arom.H ), 8.87(1H, brs, -CON H -phenyl-CH2-OH)
[0203] [ka]
[0204] Example 21: Synthesis of Compound 31 The compound of formula (30) (0.100 g, 0.054 mmol), di(N-succinimidyl) carbonate (0.058 g, 0.227 mmol), triethylamine (0.025 g, 0.243 mmol), and 2,6-di-tert-butyl-p-cresol (0.02 mg) were charged into a 6 ml screw tube containing a stirrer, and the reaction was carried out at 25°C for 2 hours. The reaction solution was washed with 0.2 M citrate phosphate buffer (pH 2.4) containing 15 wt% sodium chloride, and then washed with acetonitrile, hexane, and 0.2 M citrate phosphate buffer (pH 7.0). The organic layer was further washed with 0.2 M citrate phosphate buffer (pH 2.4) containing 15 wt% sodium chloride, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (31). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 2.17-2.33(6H, m, >CNHCO-C H 2-CH2-, -NHCO-C H2-CH2-maleimide, -OC(O)-NH-CH2-C H 2-), 2.61(4H, s, - N-succinimidyl ), 2.75-2.83(1H, m, >C H -CH2-phenyl), 3.04-3.18(4H, m, >CNHCO-CH2-C H 2-, >CNH-CH2-OC(O)-NH-C H 2-CH2-), 3.24(6H, s, -O-C H 3), 3.41-3.70(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CONH-C H 2-CONH-phenyl-CH2-OC(O)-, -C H 2-maleimide), 3.80-4.00(2H, m, >CH-C H 2-phenyl), 4.14(2H, s, >CNH-C H 2-OC(O)-NH-), 4.45-4.57(1H, m, >CCH2-N H CO-CH2-CH2-), 4.94(2H, s, -CONH-phenyl-C H 2-OC(O)O-), 6.99(2H, s, - maleimide ), 7.16-7.30(5H, m, arom.H ), 7.32(1H, brs, >CNH-CH2-OC(O)-N H -), 7.40(2H, d, -CONH- phenyl -CH2-OC(O)O-), 7.65(2H, d, -CONH- phenyl -CH2-OC(O)O-), 7.83-7.92(1H, brs, -N H CO-CH2-CH2-maleimide), 8.20-8.45(2H, m, -CON H -CH-CONH-CH2-, -CONH-CH-CON H -CH2-), 9.91(1H, brs, -CON H -phenyl-CH2-OC(O)O-)
[0205] [ka]
[0206] Example 22: Synthesis of Compound 32 The compound of formula (30) (0.100 g, 0.054 mmol), p-nitrophenyl chloroformate (0.026 g, 0.130 mmol), N-phenylmorpholine (0.026 g, 0.227 mmol), and dichloromethane (0.716 g) were placed in a 4 ml screw tube containing a stirrer and reacted for 12 hours at 25° C. Distilled water (0.016 g, 0.0756 mmol) and N-phenylmorpholine (0.044 g, 0.270 mmol) were added to quench the reaction, and the mixture was diluted with hexane and washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride. The organic layer was washed with 0.15M borate buffer (pH 10) containing 10wt% sodium chloride and 5wt% sodium dihydrogen phosphate aqueous solution containing 10wt% sodium chloride, then dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The residue was dissolved in acetonitrile, washed with hexane and t-butanol, and the solvent was removed under reduced pressure to obtain the compound of formula (32). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm):2.19-2.32(6H, m, >CNHCO-C H 2-CH2-, -NHCO-C H 2-CH2-maleimide, -OC(O)-NH-CH2-C H 2-), 2.72-2.82(1H, m, >C H -CH2-phenyl), 3.03-3.22(4H, m, >CNHCO-CH2-C H 2-, >CNH-CH2-OC(O)-NH-C H 2-CH2-), 3.23(6H, s, -OC H 3), 3.38-3.70(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O)12 -, -CONH-C H 2-CONH-phenyl-CH2-OC(O)-, -C H 2-maleimide), 3.80-3.96(2H, m, >CH-C H 2-phenyl), 4.15(2H, s, >CNH-C H 2-OC(O)-NH-), 4.45-4.56(1H, brs, >CN H CO-CH2-CH2-), 5.25(2H, s, -CONH-phenyl-C H 2-OC(O)O-), 6.99(2H, s, - maleimide ), 7.14-7.35(6H, m, arom.H , >CNH-CH2-OC(O)-N H -), 7.42(2H, d, -CONH- phenyl -CH2-OC(O)O-), 7.54-7.60(2H, m, arom.H(p-nitrophenyl) ), 7.64-7.72(2H, d, -CONH- phenyl -CH2-OC(O)O-), 7.83-7.92(1H, m, -N H CO-CH2-CH2-maleimide), 8.22-8.43(4H, m, -CON H -CH-CONH-CH2-, -CONH-CH-CON H -CH2-, arom.H(p-nitrophenyl) ), 9.90(1H, brs, -CON H -phenyl-CH2-OC(O)O-)
[0207]
change
[0208] (Example 23 Synthesis of Compound 33) The compound of formula (28) (0.100 g, 0.052 mmol), di(N-succinimidyl)carbonate (0.056 g, 0.218 mmol), triethylamine (0.024 g, 0.234 mmol), and 2,6-di-tert-butyl-p-cresol (0.02 mg) were placed in a 6 ml screw tube equipped with a stirrer, and the reaction was carried out at 25° C. for 2 hours. Thereafter, purification was carried out in the same manner as in Example 16 to obtain the compound of formula (33). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.20-2.45(4H, m, >CCH2-NHCO-C H 2-CH2-, -OC(O)-NH-CH2-C H 2-), 2.82(4H, s, - N-succinimidyl ), 3.38(6H, s, -OC H 3), 2.90-3.80(108H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, -CH-C H 2-phenyl, >CNH-CH2-OC(O)-NH-C H 2-CH2-, >CCH2-NHCO-CH2-C H 2-NHCO-, -CONH-C H 2-CONH-phenyl-CH2-), 3.80-4.65(8H, -NH-C(O)OC H 2-Fmoc, >CNH-C H 2-OC(O)-NH-, -CH2- Fmoc(CH) , -(CH2)2-CON H -CH-CONH-CH2-, -(CH2)2-CONH-CH-CON H -CH2-, -(CH2)2-CONH-C H -CONH-CH2-), 5.26(2H, s, -CONH-phenyl-C H 2-OC(O)O-), 6.02-6.15(2H, m, -N H -C(O)O-CH2-Fmoc, >CNH-CH2-OC(O)-N H-), 6.53(1H, brs, >CCH2-N H CO-CH2-CH2-), 7.11-7.84(17H, m, arom.H ), 8.89(1H, brs, -CON H -phenyl-CH2-OC(O)O-)
[0209] [ka]
[0210] Example 24: Synthesis of Compound 34 A 14 mL screw tube containing a stirrer was charged with the compound of formula (27) (0.300 g, 0.186 mmol), L-valine-citrulline (H-Val-Cit-pAB) (0.088 g, 0.233 mmol, Watanabe Chemical Industry Co., Ltd.) condensed with p-aminobenzyl alcohol (pAB) at the C-terminus, DMT-MM (0.080 g, 0.233 mmol), acetonitrile (3.00 g), and N,N-diisopropylethylamine (0.031 g, 0.242 mmol), and reacted at 25°C for 2 hours. After adding a 5 wt% aqueous solution of sodium dihydrogen phosphate (1.80 g), the acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene. Thereafter, purification was performed in the same manner as in Example 5 to obtain a compound of formula (34). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm):0.76-0.92(6H, m, >CH-CH(C H 3)2), 1.30-1.48(2H, m, -CH2-C H 2-CH2-NHCO-NH2), 1.55-1.78(2H, m, -C H 2-CH2-CH2-NHCO-NH2), 1.92-2.04(1H, m, >CH-C H (CH3)2), 2.22-2.44(4H, m, >CNHCO-C H 2-CH2-NHCO-, >CCH2-O-CONH-CH2-C H 2-), 2.87-3.10(2H, m, -CH2-CH2-CH 2-NHCO-NH2), 3.23(6H, s, -O-C H 3), 3.40-3.72(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -,>CNHCO-CH2-C H 2-NHCO-, >CCH2-O-CONH-C H 2-CH2-), 4.15(2H, brs, >CC H 2-O-CONH-), 4.18-4.24(2H, m, -CH2- Fmoc(CH) , >C H -CH(CH3)2), 4.25-4.32(2H, m, -C H 2-Fmoc(CH)), 4.36-4.42(1H, m, >C H -CH2-CH2-CH2-NHCO-NH2), 4.42(2H, d, -CONH-phenyl-C H 2-OH), 5.08(1H, t, -CONH-phenyl-CH2-O H ), 5.40(2H, brs, -CH2-CH2-CH2-NHCO-N H 2), 5.94-6.05(1H, m, -CH2-CH2-CH2-N H CO-NH2), 7.02-7.10(1H, m, >CCH2-O-CON H -CH2-CH2-), 7.16-7.28(3H, m, >CNHCO-CH2-CH2-N H CO-, -CONH- phenyl -CH2-OH), 7.31-7.47(5H, m, >CN H CO-CH2-CH2-NHCO-, arom.H(Fmoc) ), 7.54(2H, d, -CONH- phenyl -CH2-OH), 7.67(2H, d, arom.H(Fmoc) ), 7.83-8.16(4H, m, -(CH2)2-CON H -CH-CONH-CH-, -(CH2)2-CONH-CH-CON H -CH-, arom.H(Fmoc)), 9.88(1H, brs, -CON H -phenyl-CH2-OH)
[0211] [ka]
[0212] Example 25: Synthesis of Compound 35 The compound of formula (34) (0.150 g, 0.076 mmol), piperidine (0.120 g, 1.52 mmol), and chloroform (1.34 g) were added to a 9 mL screw tube containing a stirrer, and the reaction was carried out at 25°C for 3 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride, and then the organic layer was diluted with toluene, and extracted into the aqueous layer using distilled water. The aqueous layer was adjusted to pH 10 using 400 g / L sodium hydroxide aqueous solution, and then washed with toluene and chloroform. After that, sodium chloride was dissolved in the aqueous layer to make 15 wt% saline, and extraction was carried out using chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure to obtain the compound of formula (35). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.76-0.92(6H, m, >CH-CH(C H 3)2), 1.30-1.50(2H, m, -CH2-C H 2-CH2-NHCO-NH2), 1.52-1.75(2H, m, -C H 2-CH2-CH2-NHCO-NH2), 1.92-2.02(1H, m, >CH-C H (CH3)2), 2.13-2.43(4H, m, >CNHCO-C H 2-CH2-NH2, >CCH2-O-CONH-CH2-C H 2-), 2.68-2.80(2H, m, >CNHCO-CH2-C H 2-NH2), 2.87-3.08(2H, m, -CH2-CH2-C H 2-NHCO-NH2), 3.24(6H, s, -OC H3), 3.15-3.70(102H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CCH2-O-CONH-C H 2-CH2-), 4.16(2H, brs, >CC H 2-O-CONH-), 4.20(1H, t, >C H -CH(CH3)2), 4.36-4.41(1H, m, >C H -CH2-CH2-CH2-NHCO-NH2), 4.42(2H, d, -CONH-phenyl-C H 2-OH), 5.08(1H, brs, -CONH-phenyl-CH2-O H ), 5.41(2H, brs, -CH2-CH2-CH2-NHCO-N H 2), 6.00(1H, brs, -CH2-CH2-CH2-N H CO-NH2), 7.04(1H, brs, >CCH2-O-CON H -CH2-CH2-), 7.18-7.28(2H, m, -CONH- phenyl -CH2-OH), 7.48-7.63(3H, m, -CONH- phenyl -CH2-OH, >CN H CO-CH2-CH2-NH2), 7.89-8.20(2H, m, -(CH2)2-CON H -CH-CONH-CH-, -(CH2)2-CONH-CH-CON H -CH-), 9.89(1H, brs, -CON H -phenyl-CH2-OH)
[0213]
change
[0214] (Example 26 Synthesis of Compound 36) The compound of formula (35) (0.100 g, 0.057 mmol), 3-maleimidopropionic acid (0.011 g, 0.063 mmol), DMT-MM (0.022 g, 0.063 mmol), triethylamine (6.9 mg, 0.068 mmol), and acetonitrile (0.900 g) were added to a 6 ml screw tube containing a stirrer, and the reaction was carried out at 25° C. for 2 hours under light-shielded conditions. After adding 0.2 M citrate phosphate buffer (pH 3.0) (1.20 g), the acetonitrile was distilled off under reduced pressure, and the aqueous layer was washed with toluene. Thereafter, purification was carried out in the same manner as in Example 20 to obtain the compound of formula (36). 1 H-NMR(CDCl3, internal standard TMS); δ(ppm):0.76-0.92(6H, m, >CH-CH(C H 3)2), 1.32-1.48(2H, m, -CH2-C H 2-CH2-NHCO-NH2), 1.52-1.77(2H, m, -C H 2-CH2-CH2-NHCO-NH2), 1.93-2.02(1H, m, >CH-C H (CH3)2), 2.17-2.44(6H, m, >CNHCO-C H 2-CH2-NHCO-CH2-CH2-, >CNHCO-CH2-CH2-NHCO-C H 2-CH2-, >CCH2-O-CONH-CH2-C H 2-), 2.87-3.08(2H, m, -CH2-CH2-C H 2-NHCO-NH2), 3.24(6H, s, -OC H 3), 3.13-3.74(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-CH2-C H 2-NHCO-CH2-CH2-, >CNHCO-CH2-CH2-NHCO-CH2-C H 2-, >CCH2-O-CONH-C H 2-CH2-), 4.15(2H, brs, >CC H2-O-CONH-), 4.16-4.23(1H, m, >C H -CH(CH3)2), 4.34-4.41(1H, m, >C H -CH2-CH2-CH2-NHCO-NH2), 4.42(2H, d, -CONH-phenyl-C H 2-OH), 5.08(1H, t, -CONH-phenyl-CH2-O H ), 5.40(2H, brs, -CH2-CH2-CH2-NHCO-N H 2), 5.99(1H, brs, -CH2-CH2-CH2-N H CO-NH2), 7.00(2H, s, - maleimide ), 7.04(1H, brs, >CCH2-O-CON H -CH2-CH2-), 7.22-7.32(3H, m, -CONH- phenyl -CH2-OH, >CN H CO-CH2-CH2-), 7.54(2H, d, -CONH- phenyl -CH2-OH), 7.88-8.16(3H, m, >CNHCO-CH2-CH2-N H CO-, -(CH2)2-CON H -CH-CONH-CH-, -(CH2)2-CONH-CH-CON H -CH-), 9.88(1H, brs, -CON H -phenyl-CH2-OH)
[0215]
change
[0216] (Example 27 Synthesis of Compound 37) The compound of formula (36) (0.100 g, 0.0483 mmol), bis(4-nitrophenyl) carbonate (0.029 g, 0.0966 mmol), N,N-diisopropylamine (0.0094 g, 0.0725 mmol), and dichloromethane (0.640 g) were charged into a 4 ml screw tube containing a stirrer, and the reaction was carried out at 25°C for 3 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride. The organic layer was further washed with 0.15 M borate buffer (pH 10) containing 10 wt% sodium chloride and 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% sodium chloride, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure. The residue was dissolved in acetonitrile, washed with hexane and t-butanol, and the solvent was distilled off under reduced pressure to obtain the compound of formula (37). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.78-0.92(6H, m, >CH-CH(C H 3)2), 1.32-1.52(2H, m, -CH2-C H 2-CH2-NHCO-NH2), 1.54-1.80(2H, m, -C H 2-CH2-CH2-NHCO-NH2), 1.93-2.02(1H, m, >CH-C H (CH3)2), 2.16-2.42(6H, m, >CNHCO-C H 2-CH2-NHCO-, >CNHCO-CH2-CH2-NHCO-C H 2-CH2-, >CCH2-O-CONH-CH2-C H 2-), 2.90-3.08(2H, m, -CH2-CH2-C H 2-NHCO-NH2), 3.24(6H, s, -OC H 3), 3.13-3.75(106H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-CH2-C H 2-NHCO-, >CNHCO-CH2-CH2-NHCO-CH2-C H 2-, >CCH2-O-CONH-CH (2-CH2-), 4.15 (2H, brs, >CC H (2-O-CONH-), 4.20 (1H, t, >C H -CH(CH3)2), 4.33 - 4.46 (1H, m, >C H -CH2-CH2-CH2-NHCO-NH2), 5.24 (2H, brs, -CONH-phenyl-C H (2-O-), 5.42 (2H, brs, -CH2-CH2-CH2-NHCO-N H 2), 6.00 (1H, brs, -CH2-CH2-CH2-N H CO-NH2), 7.00 (2H, s, - maleimide ), 7.05 (1H, brs, >CCH2-O-CON H -CH2-CH2-), 7.32 (1H, brs, >CN H CO-CH2-CH2-NHCO-), 7.37 - 7.47 (2H, m, -CONH- phenyl -CH2-O-), 7.57 (2H, d, arom.H(p-nitrophenyl) ), 7.63 - 7.68 (2H, m, -CONH- phenyl -CH2-O-), 7.80 - 8.18 (3H, m, >CNHCO-CH2-CH2-N H CO-, -(CH2)2-CON H -CH-CONH-CH-, -(CH2)2-CONH-CH-CON H -CH-), 8.31 (2H, d, arom.H(p-nitrophenyl) ), 10.1 (1H, brs, -CON H -phenyl-CH2-O-)
[0217] [Chemical formula]
[0218] (Synthesis of Compound 38 in Example 28) The compound of formula (34) (0.100 g, 0.0506 mmol), bis(4-nitrophenyl) carbonate (0.031 g, 0.101 mmol), N,N-diisopropylamine (0.0098 g, 0.0759 mmol), and dichloromethane (0.671 g) were charged into a 4 ml screw tube containing a stirrer, and the reaction was carried out at 25°C for 3 hours. The reaction solution was washed with 0.2 M hydrochloric acid containing 20 wt% sodium chloride. The organic layer was further washed with 0.15 M borate buffer (pH 10) containing 10 wt% sodium chloride and 5 wt% sodium dihydrogen phosphate aqueous solution containing 20 wt% sodium chloride, dried over anhydrous sodium sulfate, filtered, and the solvent was distilled off under reduced pressure. The residue was dissolved in acetonitrile, washed with hexane and t-butanol, and the solvent was distilled off under reduced pressure to obtain the compound of formula (38). 1 H-NMR (DMSO-d6, internal standard TMS); δ(ppm): 0.77-0.90(6H, m, >CH-CH(C H 3)2), 1.33-1.51(2H, m, -CH2-C H 2-CH2-NHCO-NH2), 1.53-1.78(2H, m, -C H 2-CH2-CH2-NHCO-NH2), 1.93-2.03(1H, m, >CH-C H (CH3)2), 2.22-2.43(4H, m, >CNHCO-C H 2-CH2-NHCO-, >CCH2-O-CONH-CH2-C H 2-), 2.87-3.15(2H, m, -CH2-CH2-C H 2-NHCO-NH2), 3.23(6H, s, -OC H 3), 3.13-3.70(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNHCO-CH2-C H 2-NHCO-, >CCH2-O-CONH-C H 2-CH2-), 4.13-4.23(4H, m, >CC H 2-O-CONH-, -CH2- Fmoc(CH) , >CH -CH(CH3)2), 4.24-4.29(2H, m, -C H 2-Fmoc(CH)), 4.36-4.42(1H, m, >C H -CH2-CH2-CH2-NHCO-NH2), 5.24(2H, brs, -CONH-phenyl-C H 2-OH), 5.41(2H, brs, -CH2-CH2-CH2-NHCO-N H 2), 6.00(1H, brs, -CH2-CH2-CH2-N H CO-NH2), 7.04(1H, brs, >CCH2-O-CON H -CH2-CH2-), 7.19(1H, brs, >CNHCO-CH2-CH2-N H CO-), 7.31-7.38(3H, m, >CN H CO-CH2-CH2-NHCO-, arom.H(Fmoc) ), 7.38-7.46(4H, m, -CONH- phenyl -CH2-OH, arom.H(Fmoc) ), 7.56-7.71(6H, m, -CONH- phenyl -CH2-OH, arom.H(Fmoc, p-nitrophenyl) ), 7.87-8.20(4H, m, -(CH2)2-CON H -CH-CONH-CH-, -(CH2)2-CONH-CH-CON H -CH-, arom.H(Fmoc) ), 8.28-8.33(2H, m, arom.H(p-nitrophenyl) ), 10.1(1H, brs, -CON H -phenyl-CH2-OH)
[0219]
change
[0220] (Example 29 Compound 31 Tetrafluoroethylene) Doxorubicin hydrochloride (2.62 mg, 4.51 μmol), N,N-diisopropylamine (1.55 mg, 11.5 μmol), N,N-dimethylformamide, and the compound of formula (31) (10.0 mg, 5.01 μmol) were placed in a 4 ml screw tube containing a stirrer, and the reaction was carried out at 25° C. for 4 hours. The reaction solution was diluted with dichloromethane, and then washed with a 5 wt% aqueous solution of sodium dihydrogen phosphate and ion-exchanged water. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the drug-linker compound of formula (39).
[0221] [ka]
[0222] Example 30: Conjugate of Compound 33 and Doxorubicin Doxorubicin hydrochloride (2.53 mg, 4.36 μmol), N,N-diisopropylamine (1.50 mg, 11.1 μmol), N,N-dimethylformamide, and the compound of formula (33) (10.0 mg, 4.84 μmol) were placed in a 4 ml screw tube equipped with a stirrer, and the reaction was carried out at 25° C. for 4 hours. Thereafter, purification was carried out in the same manner as in Example 29, and a drug-linker compound of formula (40) was obtained.
[0223] [ka]
[0224] Example 31 Conjugate of Compound 37 and Doxorubicin Doxorubicin hydrochloride (2.62 mg, 4.51 μmol), N,N-diisopropylamine (1.55 mg, 11.5 μmol), N,N-dimethylformamide, and the compound of formula (37) (10.4 mg, 5.01 μmol) were charged into a 4 ml screw tube containing a stirrer, and the reaction was carried out at 25° C. for 4 hours. The reaction solution was diluted with dichloromethane, and then washed with a 5 wt% aqueous solution of sodium dihydrogen phosphate, a 5 wt% aqueous solution of disodium hydrogen phosphate, and ion-exchanged water. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the drug-linker compound of formula (41).
[0225] [ka]
[0226] Example 32: Conjugate of Compound 38 and Doxorubicin Doxorubicin hydrochloride (2.53 mg, 4.36 μmol), N,N-diisopropylamine (1.50 mg, 11.1 μmol), N,N-dimethylformamide, and the compound of formula (38) (10.4 mg, 4.84 μmol) were placed in a 4 ml screw tube equipped with a stirrer, and the reaction was carried out at 25° C. for 4 hours. Thereafter, purification was carried out in the same manner as in Example 31, and a drug-linker compound of formula (42) was obtained.
[0227] [ka]
[0228] Example 33 Preparation of ADC using compound 39 A monoclonal anti-interleukin-1β antibody produced in a mouse (0.500 mg, Sigma-Aldrich) was dissolved in phosphate-buffered saline (PBS, 0.500 mL). 0.048 mL of this solution was placed in a 0.5 mL polypropylene tube, to which 50.0 mM ethylenediaminetetraacetic acid (EDTA, 0.006 mL) and 0.800 mM aqueous tris(2-carboxymethyl)phosphine hydrochloride (TCEP) (0.006 mL; 15 equivalents relative to the antibody) were added, and the mixture was shaken at 37°C for 1 hour. A 2.50 mM N,N-dimethylacetamide solution of the compound of formula (39) (0.007 mL; 53 equivalents relative to the antibody) was added to the above solution, and the mixture was further shaken at 20°C for 1 hour. A 2.50 mM aqueous solution of N-acetylcysteine (0.007 mL; 53 equivalents relative to the antibody) was added, and the resulting mixture was further shaken at 20°C for 1 hour. The solution obtained above was loaded onto a NAP-5 column (GE Healthcare Life Science) equilibrated with PBS (10 mL), and the antibody fraction was isolated by elution with PBS.
[0229] Example 34 Preparation of ADC using compound 41 A monoclonal anti-interleukin-1β antibody produced in a mouse (0.500 mg, Sigma-Aldrich) was dissolved in phosphate-buffered saline (PBS, 0.500 mL). 0.048 mL of this solution was placed in a 0.5 mL polypropylene tube, to which 50.0 mM ethylenediaminetetraacetic acid (EDTA, 0.006 mL) and 0.800 mM aqueous tris(2-carboxymethyl)phosphine hydrochloride (TCEP) (0.006 mL; 15 equivalents relative to the antibody) were added, and the mixture was shaken at 37°C for 1 hour. A 2.50 mM N,N-dimethylacetamide solution of the compound of formula (41) (0.007 mL; 53 equivalents relative to the antibody) was added to the above solution, and the mixture was further shaken at 20°C for 1 hour. A 2.50 mM aqueous solution of N-acetylcysteine (0.007 mL; 53 equivalents relative to the antibody) was added, and the resulting mixture was further shaken at 20°C for 1 hour. The solution obtained above was loaded onto a NAP-5 column (GE Healthcare Life Science) equilibrated with PBS (10 mL), and the antibody fraction was isolated by elution with PBS.
[0230] Example 35: Calculation of the average number of drugs bound per antibody in ADC using compound 39 The average number of bonds per antibody in an antibody-drug conjugate can be calculated by measuring the UV absorbance of an aqueous solution of the antibody-drug conjugate at two wavelengths, 280 nm and 495 nm, and then performing the following calculation. Since the total absorbance at a certain wavelength is equal to the sum of the absorbance of all absorbing chemical species present in the system (additivity of absorbance), if we assume that there is no change in the molar absorption coefficients of the antibody and drug before and after the conjugation reaction between the antibody and drug, the antibody concentrations and drug concentrations in the antibody-drug complex are expressed by the following relational equations. A280=AD,280+AA,280=εD,280CD+εA,280CA Formula (i) A495=AD,495+AA,495=εD,495CD+εA,495CA Formula (ii) Here, A280 indicates the absorbance of the antibody-drug complex aqueous solution at 280 nm, A495 indicates the absorbance of the antibody-drug complex aqueous solution at 495 nm, AA,280 indicates the absorbance of the antibody at 280 nm, AA,495 indicates the absorbance of the antibody at 495 nm, AD,280 indicates the absorbance of the drug-linker compound at 280 nm, AD,495 indicates the absorbance of the drug-linker compound at 495 nm, εA,280 indicates the molar absorption coefficient of the antibody at 280 nm, εA,495 indicates the molar absorption coefficient of the antibody at 495 nm, εD,280 indicates the molar absorption coefficient of the drug-linker compound at 280 nm, εD,495 indicates the molar absorption coefficient of the drug-linker compound at 495 nm, CA indicates the antibody concentration in the antibody-drug complex, and CD indicates the drug concentration in the antibody-drug complex. Here, εA,280, εA,495, εD,280, and εD,495 are values prepared in advance (estimated values or measured values obtained from UV measurement of the compound). εA,495 is usually zero. εD,280 and εD,495 can be obtained by measuring the absorbance of a solution in which the drug-linker compound used is dissolved at a certain molar concentration, according to the Beer-Lambert law (absorbance = molar concentration × molar extinction coefficient × cell path length). CA and CD can be calculated by measuring A280 and A495 of the antibody-drug complex solution, substituting these values into equations (i) and (ii) and solving the simultaneous equations. Furthermore, the average number of drugs bound per antibody can be calculated by dividing CD by CA. The above simultaneous equations were solved using the molar extinction coefficients εA,280 = 206,999 (estimated value), εA,495 = 0, εD,280 = 10426 (measured value), and εD,495 = 10339 (measured value), and the average number of drugs bound per antibody was found to be 7.8.
[0231] Example 36: Calculation of the average number of drugs bound per antibody in ADC using compound 41 Calculations were performed in the same manner as in Example 35 using the molar extinction coefficients εA,280 = 206,999 (estimated value), εA,495 = 0, εD,280 = 9837 (measured value), and εD,495 = 9785 (measured value), and the average number of drugs bound per antibody was 8.1.
[0232] (Comparative Example 1: Synthesis of Compound 43) A 50 mL three-neck flask equipped with a thermometer, nitrogen inlet, stirrer, Dean-Stark tube, and condenser was charged with the compound of formula (14) (0.800 g, 0.663 mmol), 6-maleimidohexanoic acid (0.161 g, 0.762 mmol), DMT-MM (0.263 g, 0.762 mmol), acetonitrile (8.00 g), and triethylamine (0.081 g, 0.796 mmol), and the reaction was carried out at 25°C for 7 hours. After adding pH 3.0 citrate-phosphate buffer (pH 3.0), the mixture was washed with toluene. After extraction with chloroform, the organic layer was washed with 10% saline. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain the compound of formula (43). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 1.31(2H, m, -C H 2CH2CH2-CONH-), 1.62(4H, m, -C H 2CH2C H 2CH2-CONH-), 2.18(2H, t, -C H 2-CONH-), 3.38(6H, s, -OC H 3), 3.40-3.85(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CNH-C H 2-OH, -C H 2-maleimide), 4.62(1H, t, -O H ), 6.23(1H, s, -CH2-CON H -), 6.69(2H, s, - maleimide )
[0233] [ka]
[0234] (Comparative Example 2: Reaction of Compound 43 with Glutathione) A 4 ml screw tube equipped with a stirrer was charged with the compound of formula (43) (1 mg) and an aqueous solution of 10 mM glutathione / 25 mM sodium acetate / 1 mM ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) (1 ml) adjusted to pH 5 with acetic acid, and the mixture was reacted at 25° C. for 3 hours in the dark to obtain an aqueous solution containing the compound of formula (44).
[0235] [ka]
[0236] (Comparative Example 3: Synthesis of Compound 45) The compound of formula (27) (0.100 g, 0.062 mmol), N-hydroxysuccinimide (0.015 g, 0.133 mmol), dimethylaminopropylethylcarbodiimide hydrochloride (0.023 g, 0.121 mmol), and chloroform (0.574 g) were added to a 4 ml screw tube containing a stirrer, and the reaction was carried out at 25° C. for 4 hours. Thereafter, purification was carried out in the same manner as in Example 9 to obtain the compound of formula (45). 1 H-NMR (CDCl3, internal standard TMS); δ(ppm): 2.28-2.43(2H, m, -OC(O)-NH-CH2-C H 2-COO-), 2.75-2.92(6H, m, >CCH2-NHCO-C H 2-CH2-, - N-succinimidyl ), 3.38(6H, s, -OC H 3), 3.35-3.90(104H, m, >C(C H 2O)2-, -O-(C H 2C H 2O) 12 -, >CCH2-NHCO-CH2-C H2-NHCO-, -OC(O)-NH-C H 2-CH2-COO-), 4.19-4.23(1H, m, -NH-C(O)O-CH2- Fmoc(CH) ), 4.35-4.50(4H, m, >CNH-C H 2-OC(O)-NH-, -NH-C(O)OC H 2-Fmoc), 5.62(1H, brs, >CNH-CH2-OC(O)-N H -), 5.88(1H, brs, -N H -C(O)O-CH2-Fmoc), 6.29(1H, brs, >CCH2-N H CO-CH2-), 7.26-7.78(8H, m, arom.H )
[0237] [ka]
[0238] Comparative Example 4: Conjugate of Compound 45 and Doxorubicin Doxorubicin hydrochloride (3.05 mg, 4.36 μmol), N,N-diisopropylamine (1.82 mg, 13.4 μmol), N,N-dimethylformamide, and the compound of formula (45) (10.0 mg, 5.84 μmol) were placed in a 4 ml screw tube equipped with a stirrer, and the reaction was carried out at 25° C. for 4 hours. Thereafter, purification was carried out in the same manner as in Example 29, and the drug-linker compound of formula (46) was obtained.
[0239] [ka]
[0240] (Example 37) Degradation test of compounds 20 and 44 using cathepsin B A peptide degradation test using cathepsin B, a protease in lysosome, was carried out for the compound of formula (20) obtained in Example 10 and the compound of formula (44) obtained in Comparative Example 2. A 4 ml screw tube was charged with human liver-derived cathepsin B buffer solution (25 μg, ≧1500 units / mg protein, Sigma-Aldrich) and a 25 mM sodium acetate / 1 mM EDTA aqueous solution (0.500 ml) adjusted to pH 5 with acetic acid to obtain a cathepsin B diluted solution. In addition, a 4 ml screw tube was charged with a diluted cathepsin B solution (0.160 ml) and a 30 mM DTT / 25 mM sodium acetate / 15 mM EDTA aqueous solution (0.320 ml) adjusted to pH 5, and left to stand at 25° C. for 15 minutes, and then mixed with a 25 mM sodium acetate / 1 mM EDTA aqueous solution (1.32 ml) at pH 5 preheated to 37° C. and an aqueous solution (0.200 ml) containing 0.1 mg / ml of the compound of formula (20) or formula (44). At the same time, a control aqueous solution not containing cathepsin B and DTT was prepared by mixing with a 25 mM sodium acetate / 1 mM EDTA aqueous solution (1.80 ml) at pH 5 preheated to 37° C. and an aqueous solution (0.200 ml) containing 0.1 mg / ml of the compound of formula (20) or formula (44). The prepared aqueous solutions (containing / not containing cathepsin B) were incubated at 37° C., and samples were taken, followed by HPLC measurement under the following measurement conditions. Charts of the measurement results are shown in FIGS. As a result, the compound of formula (20) of the present invention was detected at a retention time of 12.9 minutes in the chart of FIG. 1, but new peaks were detected at retention times of 10.9 minutes and 7.7 minutes after the test with cathepsin B, and the molecular weight of the new peaks matched the fragments decomposed at the C-terminus of glycine in the compound of formula (20) from the results of the mass chromatogram in FIG. 2. On the other hand, the compound of formula (44) of the comparative example was detected at a retention time of 11.9 minutes in the chart of FIG. 3, and no new peaks were detected after the test with cathepsin B. Therefore, since only the compound of formula (20) having a peptide linker was specifically cleaved by cathepsin B, it was found that the peptide linker portion of the heterobifunctional monodisperse polyethylene glycol of the present invention was cleaved in an intracellular enzyme-dependent manner. HPLC equipment: Alliance (Waters) Column: Sun Shell C18 (3.0×150mm, 2.6μm; Chromanik Technologies, Inc.) ·Flow rate: 0.6mL / min ·Analysis time: 30 minutes Column temperature: 40℃ ·Injection volume: 5μL Detector: Mass spectrometer (ionization: ESI) Mobile phase A: 0.1M formic acid / water Mobile phase B: 0.1M formic acid / acetonitrile Gradient programs: 10%-50% (0 min-20 min), 50%-95% (20 min-25 min), 95%-10% (25 min-30 min)
[0241] (Example 38: Decomposition test of compounds 21 and 26 using cathepsin B) A peptide degradation test was carried out using cathepsin B, a protease in lysosome, for the compound of formula (21) obtained in Example 11 and the compound of formula (26) obtained in Example 16. Thereafter, the degradation test and HPLC measurement were carried out under the same conditions as in Example 37. Charts of the measurement results are shown in Figures 4 to 6. As a result, the compound of the present invention, formula (21), was detected at a retention time of 13.8 minutes in the chart of FIG. 4, but new peaks were detected at retention times of 13.6 minutes and 7.5 minutes after the test with cathepsin B, and the molecular weight of the new peaks matched the fragments decomposed at the C-terminus of glycine in the compound of formula (21) from the results of the mass chromatogram in FIG. 5. On the other hand, the compound of formula (26) was detected at a retention time of 13.5 minutes in the chart of FIG. 6, and no new peaks were detected after the test with cathepsin B. Therefore, since only the compound of formula (21) having a peptide linker was specifically cleaved by cathepsin B, it was found that the peptide linker portion of the heterobifunctional monodisperse polyethylene glycol of the present invention was cleaved in an intracellular enzyme-dependent manner.
[0242] (Example 39) Degradation test of drug-linker compounds 40 and 46 using cathepsin B For the drug-linker compound of formula (40) obtained in Example 30 and the drug-linker compound of formula (46) obtained in Comparative Example 4, a peptide degradation test was carried out using cathepsin B, a protease in lysosome. Thereafter, the test was carried out in the same manner as in Example 37, and HPLC measurement was carried out under the following measurement conditions. Charts of the measurement results are shown in Figures 7 to 9. As a result, the drug-linker compound of formula (40) of the present invention was detected at a retention time of 16.8 minutes in the chart of FIG. 7, but after the test with cathepsin B, a new peak was detected at a retention time of 6.8 minutes. From the mass chromatogram results of FIG. 8, the new peak was consistent with doxorubicin. On the other hand, the drug-linker compound of formula (46) of the comparative example was detected at a retention time of 14.7 minutes in the chart of FIG. 9, and no new peak was observed even after the test with cathepsin B. Therefore, it was found that when the heterobifunctional monodisperse polyethylene glycol of the present invention has a para-aminobenzyl alcohol group at the C-terminus of the peptide, the para-aminobenzyl alcohol group is also eliminated by cleavage of the peptide linker, and the drug can be released in a chemically unmodified structure. HPLC equipment: Alliance (Waters) Column: Sun Shell C18 (3.0×150mm, 2.6μm; Chromanik Technologies, Inc.) ·Flow rate: 0.6mL / min ·Analysis time: 30 minutes Column temperature: 40℃ ·Injection volume: 5μL Detector: Mass spectrometer (ionization: ESI), photodiode array (PDA) (wavelength: 480 nm) Mobile phase A: 0.1M formic acid / water Mobile phase B: 0.1M formic acid / acetonitrile Gradient programs: 10%-80% (0 min-20 min), 80%-95% (20 min-25 min), 95%-10% (25 min-30 min)
[0243] (Example 40: Degradation test of drug-linker compounds 42 and 46 using cathepsin B) A peptide degradation test was carried out using cathepsin B, a protease in lysosome, for the drug-linker compound of formula (42) obtained in Example 32 and the drug-linker compound of formula (46) obtained in Comparative Example 4. Thereafter, the degradation test and HPLC measurement were carried out under the same conditions as in Example 39. A chart of the measurement results is shown in FIG. As a result, in the drug-linker compound of formula (42) of the present invention, a new peak was detected at a retention time of 6.8 minutes after the test with cathepsin B, as in Example 39, and the new peak was found to be consistent with doxorubicin from the mass chromatogram results. On the other hand, in the drug-linker compound of formula (46) of the comparative example, no new peak was observed even after the test with cathepsin B. Therefore, it was found that in the heterobifunctional monodisperse polyethylene glycol of the present invention, when the peptide has a para-aminobenzyl alcohol group at the C-terminus, the para-aminobenzyl alcohol group is also eliminated by cleavage of the peptide linker, and the drug can be released in a chemically unmodified structure.
[0244] Example 41: Cytotoxicity test using drug-linker compounds 40 and 46 A cell suspension was prepared at 5000 cells / well using 10 mL of RPMI-1640 medium (10% FBS Pn / St) and 80% confluent HeLa cells, and the cell suspension was dispensed into each plate of a 96-well microplate. After culturing for 24 hours in a carbon dioxide incubator, the medium was replaced, and a medium in which the drug-linker compound of formula (40) obtained in Example 30 or the compound of formula (46) obtained in Comparative Example 4 was dissolved at various concentrations was added, and the cells were cultured at 37°C for 24 hours. Cell Counting Kit-8 solution (manufactured by Dojindo Chemical Industries, Ltd.) was added to each well of the microplate, and a color reaction was carried out for 2 hours in a carbon dioxide incubator. The absorbance at 450 nm was measured using a microplate reader, and the cell viability was calculated using the following formula to evaluate the cytotoxicity of the drug. The cell viability at each concentration is shown in Figure 11. Cell viability (%)=[(Asample -A blank ) / (A cell -A blank )] x 100 A sample : absorbance of the sample, A cell : Absorbance of cells only, without sample A blank : Absorbance of blank containing no cells As a result, the drug-linker compound of the present invention represented by formula (40) exhibited cytotoxicity, as the cell viability decreased depending on the sample concentration. On the other hand, the compound of the comparative example represented by formula (46) exhibited high cell viability even under high sample concentration conditions, and did not exhibit cytotoxicity. Therefore, it was found that the drug-linker compound using the heterobifunctional monodisperse polyethylene glycol of the present invention has higher cytotoxicity and can release the drug inside the cells, compared to the drug-linker compound of the comparative example that does not contain a peptide linker.
[0245] (Example 42) Cytotoxicity test using drug-linker compounds 42 and 46 A cell suspension was prepared at 5000 cells / well using 10 mL of RPMI-1640 medium (10% FBS Pn / St) and 80% confluent HeLa cells, and the cell suspension was dispensed into each plate of a 96-well microplate. After culturing for 24 hours in a carbon dioxide incubator, the medium was replaced, and a medium in which the drug-linker compound of formula (42) obtained in Example 32 or the compound of formula (46) obtained in Comparative Example 4 was dissolved at various concentrations was added, and the cells were cultured at 37°C for 24 hours. Cell Counting Kit-8 solution (manufactured by Dojindo Chemical Industries, Ltd.) was added to each well of the microplate, and a color reaction was carried out for 2 hours in a carbon dioxide incubator. The absorbance at 450 nm was measured using a microplate reader, and the cell viability was calculated using the following formula to evaluate the cytotoxicity of the drug. The cell viability at each concentration is shown in Figure 12. Cell viability (%)=[(A sample -A blank ) / (A cell -A blank )] x 100 A sample: absorbance of the sample, A cell : Absorbance of cells only, without sample A blank : Absorbance of blank containing no cells As a result, the trend in cell viability was similar to that of Example 41, and it was found that the drug-linker compound using the heterobifunctional monodisperse polyethylene glycol of the present invention had higher cytotoxicity and was able to release the drug intracellularly compared to the comparative drug-linker compound not containing a peptide linker.
[0246] (Example 43) Evaluation of hydrophilicity of various linkers The compounds of formulae (15), (21), (28) and (34) obtained in Examples 5, 11, 18 and 24 were subjected to HPLC measurement under the following measurement conditions, and the retention times of the peaks of various linkers are shown in the table below. As a result, the retention time of the linker containing valine-citrulline was the shortest, followed by the linkers containing valine-alanine and phenylalanine-glycine in that order. Therefore, it was found that the linker containing valine-citrulline can enhance hydrophilicity more among the heterobifunctional monodisperse polyethylene glycols of the present invention. HPLC equipment: Thermo Fisher Ultimate 3000 Column: Sun Shell C18 (3.0×150mm, 2.6μm; Chromanik Technologies, Inc.) ·Flow rate: 0.6mL / min ·Analysis time: 80 minutes Column temperature: 40℃ ·Injection volume: 10μL Detector: Corona Charged Aerosol Detector (CAD) Mobile phase A: 0.1M formic acid / water Mobile phase B: 0.1M formic acid / acetonitrile Gradient program: 20%-95% (0 min-75 min), 95%-95% (75 min-80 min)
[0247] [Table 1]
[0248] The heterobifunctional monodisperse polyethylene glycol of the present invention is released from the drug by being cleaved by an enzyme within the cell, thereby suppressing the decrease in pharmacological activity caused by the presence of the linker in a bound state. [Industrial Applicability]
[0249] The heterobifunctional monodisperse polyethylene glycol of the present invention slowly releases a drug by decomposition of the peptide linker by an intracellular enzyme and has two adjacent monodisperse polyethylene glycol side chains that effectively mask the hydrophobicity of the drug, and is therefore useful for modifying biofunctional molecules such as physiologically active proteins, peptides, antibodies, nucleic acids and low-molecular-weight drugs, drug carriers in drug delivery systems, or diagnostic materials and medical devices.
[0250] This application is based on patent application No. 2019-176066 filed in Japan, the contents of which are incorporated in their entirety herein.
Claims
1. Heterobifunctional monodisperse polyethylene glycol represented by formula (1): 【Chemistry 1】 (In formula (1), X 1 and Y 1 are atomic groups each containing at least a functional group that reacts with a functional group present in a biofunctional molecule to form a covalent bond, and the atomic group X 1 The functional group and the atomic group Y 1 are different from the functional groups contained in R 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer from 3 to 72; A 1 -L 1 -(CH 2 ) m1 -L 2 -, -L 1 -(CH 2 ) m1 -L 2 -(CH 2 ) m2 represents -, an amide bond, a urethane bond, a secondary amino group, or a single bond, and m1 and m2 each independently represent an integer of 1 to 5; B 1 Ha-CH 2 -L 3 -, -CH 2 -L 3 -(CH 2 ) m3 -L 4 -or-CH 2 -L 3 -(CH 2 ) m3 -L 4 -(CH 2 ) m4 -, m3 and m4 each independently represent an integer from 1 to 5; W is an oligopeptide of 2 to 4 residues; Z is a spacer having a bifunctional para-aminobenzyl alcohol group attached to the C-terminus of the peptide; a1 and a2 are such that when a1=1, a2=0, and when a1=0, a2=1; b is 0 or 1; C 1 -L 5 -(CH 2 ) m5 -, -L 5 -(CH 2 ) m5 -L 6 -(CH 2 ) m6 -, an amide bond or a single bond, and m5 and m6 each independently represent an integer of 1 to 5; L 1 ~L 6 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, a carbonyl group, or a single bond.)
2. The heterobifunctional monodisperse polyethylene glycol according to claim 1, wherein W is an oligopeptide of 2 to 4 residues comprising at least one hydrophobic neutral amino acid selected from the group consisting of phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
3. The heterobifunctional monodisperse polyethylene glycol according to claim 1, wherein W is an oligopeptide of 2 to 4 residues containing at least one hydrophobic neutral amino acid selected from the group consisting of phenylalanine, leucine, valine, and isoleucine, and having at least one other amino acid selected from the group consisting of alanine, glycine, citrulline, proline, serine, and asparagine.
4. 2. The heterobifunctional monodisperse polyethylene glycol of claim 1, wherein W is an oligopeptide whose C-terminal amino acid is glycine.
5. 2. The heterobifunctional monodisperse polyethylene glycol of claim 1, wherein W is a dipeptide.
6. X in formula (1) 1 and Y 1 are each independently selected from the group consisting of formula (a), formula (b1), formula (b2), formula (c), formula (d1), formula (d2), formula (e), formula (f), formula (g), formula (h), formula (i), formula (j), formula (k), formula (l), formula (m), formula (n) and formula (o). The heterobifunctional monodisperse polyethylene glycol according to any one of claims 1 to 5. 【Chemistry 2】 (In formulas (d1) and (d2), R 2 is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms; in formula (e), R 3 is a halogen atom selected from a chlorine atom, a bromine atom, and an iodine atom; and in formula (l), R 4 is a hydrogen atom or a hydrocarbon group having 1 to 5 carbon atoms.
7. An antibody-drug conjugate comprising a heterobifunctional monodisperse polyethylene glycol represented by formula (2): 【Chemistry 3】 (In formula (2), X 2 and Y 2 one of which is an antibody and the other is a drug; R 1 is a hydrocarbon group having 1 to 7 carbon atoms or a hydrogen atom; n is an integer from 3 to 72; A 2 -L 1 -(CH 2 ) m1 -L 7 -, -L 1 -(CH 2 ) m1 -L 8 -, -L 1 -(CH 2 ) m1 -L 2 -(CH 2 ) m2 -L 8 -or-L 8 -, m1 and m2 each independently represent an integer from 1 to 5; B 2 Ha-CH 2 -L 9 -, -CH 2 -L 9 -(CH 2 ) m3 -L 10 -, -CH 2 -L 9 -(CH 2 ) m3 -L 10 -(CH 2 ) m4 -L 11 -, -CH 2 -L 12 -, -CH 2 -L 9 -(CH 2 ) m3 -L 12 -or-CH 2 -L 9 -(CH 2 ) m3 -L 10 -(CH 2 ) m4 -L 12 -, m3 and m4 each independently represent an integer from 1 to 5; L 1 and L 2 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, or a single bond; L 7 , L 9 , L 10 and L 11 each independently represents an ether bond, a urethane bond, an amide bond, a secondary amino group, or a carbonyl group; L 8 and L 12 represents an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing any of these, or a single bond; W is an oligopeptide of 2 to 4 residues; Z is a spacer having a bifunctional para-aminobenzyl alcohol group attached to the C-terminus of the peptide; a3 and a4 are X 2 When is a drug, a3=1 and a4=0, and Y 2 is a drug, a3=0 and a4=1; b is 0 or 1; and C 2 represents an amide bond, a urethane bond, a maleimide-thiol bond, a thioether bond, a disulfide bond, a carbonate bond, an ester bond, an ether bond, a 1H-1,2,3-triazole-1,4-diyl structure, a secondary amino group, a hydrazide group, an oxyamide group, or a hydrocarbon group containing any of these.)
8. The antibody-drug conjugate according to claim 7, wherein W is an oligopeptide of 2 to 4 residues containing at least one of hydrophobic neutral amino acids, phenylalanine, leucine, valine, and isoleucine, and the other amino acids are neutral amino acids excluding cysteine.
9. The antibody-drug conjugate according to claim 7, wherein W is an oligopeptide of 2 to 4 residues containing at least one of hydrophobic neutral amino acids phenylalanine, leucine, valine, and isoleucine, and the other amino acids having at least one of alanine, glycine, citrulline, proline, serine, and asparagine.
10. The antibody-drug conjugate of claim 7, wherein W is an oligopeptide whose C-terminal amino acid is glycine.
11. The antibody-drug conjugate of claim 7, wherein W is a dipeptide.
Citation Information
Patent Citations
Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005108463A2
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2015057699A2
Conjugates and conjugating reagents
WO2016063006A1
Heterobifunctional monodispersed polyethylene glycol, and complex using same
WO2018181059A1
Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain
WO2019176875A1
